Spaces:
Running
Running
File size: 152,057 Bytes
9754890 |
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 1565 1566 1567 1568 1569 1570 1571 1572 1573 1574 1575 1576 1577 1578 1579 1580 1581 1582 1583 1584 1585 1586 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606 1607 1608 1609 1610 1611 1612 1613 1614 1615 1616 1617 1618 1619 1620 1621 1622 1623 1624 1625 1626 1627 1628 1629 1630 1631 1632 1633 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669 1670 1671 1672 1673 1674 1675 1676 1677 1678 1679 1680 1681 1682 1683 1684 1685 1686 1687 1688 1689 1690 1691 1692 1693 1694 1695 1696 1697 1698 1699 1700 1701 1702 1703 1704 1705 1706 1707 1708 1709 1710 1711 1712 1713 1714 1715 1716 1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 1729 1730 1731 1732 1733 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1750 1751 1752 1753 1754 1755 1756 1757 1758 1759 1760 1761 1762 1763 1764 1765 1766 1767 1768 1769 1770 1771 1772 1773 1774 1775 1776 1777 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 1801 1802 1803 1804 1805 1806 1807 1808 1809 1810 1811 1812 1813 1814 1815 1816 1817 1818 1819 1820 1821 1822 1823 1824 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 1844 1845 1846 1847 1848 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 1861 1862 1863 1864 1865 1866 1867 1868 1869 1870 1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890 1891 1892 1893 1894 1895 1896 1897 1898 1899 1900 1901 1902 1903 1904 1905 1906 1907 1908 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 1925 1926 1927 1928 1929 1930 1931 1932 1933 1934 1935 1936 1937 1938 1939 1940 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 2075 2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 2086 2087 2088 2089 2090 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 2123 2124 2125 2126 2127 2128 2129 2130 2131 2132 2133 2134 2135 2136 2137 2138 2139 2140 2141 2142 2143 2144 2145 2146 2147 2148 2149 2150 2151 2152 2153 2154 2155 2156 2157 2158 2159 2160 2161 2162 2163 2164 2165 2166 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 2188 2189 2190 2191 2192 2193 2194 2195 2196 2197 2198 2199 2200 2201 2202 2203 2204 2205 2206 2207 2208 2209 2210 2211 2212 2213 2214 2215 2216 2217 2218 2219 2220 2221 2222 2223 2224 2225 2226 2227 2228 2229 2230 2231 2232 2233 2234 2235 2236 2237 2238 2239 2240 2241 2242 2243 2244 2245 2246 2247 2248 2249 2250 2251 2252 2253 2254 2255 2256 2257 2258 2259 2260 2261 2262 2263 2264 2265 2266 2267 2268 2269 2270 2271 2272 2273 2274 2275 2276 2277 2278 2279 2280 2281 2282 2283 2284 2285 2286 2287 2288 2289 2290 2291 2292 2293 2294 2295 2296 2297 2298 2299 2300 2301 2302 2303 2304 2305 2306 2307 2308 2309 2310 2311 2312 2313 2314 2315 2316 2317 2318 2319 2320 2321 2322 2323 2324 2325 2326 2327 2328 2329 2330 2331 2332 2333 2334 2335 2336 2337 2338 2339 2340 2341 2342 2343 2344 2345 2346 2347 2348 2349 2350 2351 2352 2353 2354 2355 2356 2357 2358 2359 2360 2361 2362 2363 2364 2365 2366 2367 2368 2369 2370 2371 2372 2373 2374 2375 2376 2377 2378 2379 2380 2381 2382 2383 2384 2385 2386 2387 2388 2389 2390 2391 2392 2393 2394 2395 2396 2397 2398 2399 2400 2401 2402 2403 2404 2405 2406 2407 |
{
"cells": [
{
"cell_type": "code",
"execution_count": 9,
"metadata": {},
"outputs": [],
"source": [
"from selenium import webdriver\n",
"from selenium.webdriver.common.by import By\n",
"from selenium.webdriver.support.ui import WebDriverWait\n",
"from selenium.webdriver.support import expected_conditions as EC\n",
"import csv\n",
"\n",
"\n",
"from selenium import webdriver\n",
"from selenium.webdriver.common.by import By\n",
"from selenium.webdriver.support.ui import WebDriverWait\n",
"from selenium.webdriver.support import expected_conditions as EC\n",
"import csv\n"
]
},
{
"cell_type": "code",
"execution_count": 10,
"metadata": {},
"outputs": [],
"source": [
"from selenium.common.exceptions import ElementClickInterceptedException, TimeoutException\n",
"\n",
"def fetch_clinical_trials(disease_name=\"\", freeword=\"\"):\n",
" \"\"\"\n",
" 指定された対象疾患名およびフリーワード検索に基づいてjRCTから臨床試験情報を取得します。\n",
"\n",
" Args:\n",
" disease_name (str): 対象疾患名（例: \"がん 神経膠腫 骨髄腫\"）\n",
" freeword (str): フリーワード検索（例: \"免疫療法\"）\n",
"\n",
" Returns:\n",
" list: 検索結果のリスト（[試験ID, タイトル, 対象疾患, 進捗状況, 日付, リンク]）\n",
" \"\"\"\n",
" # WebDriverを初期化\n",
" driver = webdriver.Chrome() # 必要に応じてChromeDriverを設定\n",
"\n",
" all_results = []\n",
"\n",
" try:\n",
" # jRCTの検索ページにアクセス\n",
" driver.get(\"https://jrct.niph.go.jp/search\")\n",
"\n",
" # 対象疾患名を入力\n",
" if disease_name:\n",
" disease_field = WebDriverWait(driver, 10).until(\n",
" EC.presence_of_element_located((By.ID, \"reg-plobrem-1\"))\n",
" )\n",
" disease_field.send_keys(disease_name)\n",
"\n",
" # 対象疾患名の条件を「or」に設定\n",
" condition_select = driver.find_element(By.ID, \"reg-plobrem-type\")\n",
" condition_select.find_element(By.CSS_SELECTOR, \"option[value='1']\").click()\n",
"\n",
" # フリーワード検索を入力\n",
" if freeword:\n",
" freeword_field = WebDriverWait(driver, 10).until(\n",
" EC.presence_of_element_located((By.ID, \"demo-1\"))\n",
" )\n",
" freeword_field.send_keys(freeword)\n",
"\n",
" # フリーワード検索の条件を「or」に設定\n",
" condition_select = driver.find_element(By.ID, \"others\")\n",
" condition_select.find_element(By.CSS_SELECTOR, \"option[value='1']\").click()\n",
"\n",
" # 募集中を選択\n",
" recruitment_checkbox = driver.find_element(By.ID, \"reg-recruitment-2\")\n",
" recruitment_checkbox.click()\n",
"\n",
" # 検索ボタンをクリック\n",
" try:\n",
" search_button = driver.find_element(By.NAME, \"button_type\")\n",
" driver.execute_script(\"arguments[0].scrollIntoView();\", search_button) # ボタンを画面内にスクロール\n",
" WebDriverWait(driver, 10).until(EC.element_to_be_clickable((By.NAME, \"button_type\"))).click()\n",
" except ElementClickInterceptedException:\n",
" print(\"検索ボタンがクリックできないため、JavaScriptでクリックします。\")\n",
" driver.execute_script(\"arguments[0].click();\", search_button)\n",
"\n",
" # ページネーション対応ループ\n",
" while True:\n",
" # 現在のページの結果がロードされるのを待機\n",
" WebDriverWait(driver, 10).until(\n",
" EC.presence_of_element_located((By.CSS_SELECTOR, \"table tbody tr\"))\n",
" )\n",
"\n",
" # 現在のページの結果を取得\n",
" rows = driver.find_elements(By.CSS_SELECTOR, \"table tbody tr\")\n",
" for row in rows:\n",
" columns = row.find_elements(By.TAG_NAME, \"td\")\n",
" if len(columns) > 4:\n",
" # 試験情報をリストに追加\n",
" trial_id = columns[0].text\n",
" title = columns[1].text\n",
" condition = columns[2].text\n",
" status = columns[3].text\n",
" date = columns[4].text\n",
"\n",
" # リンクを取得（エラー処理を追加）\n",
" try:\n",
" link = columns[1].find_element(By.TAG_NAME, \"a\").get_attribute(\"href\")\n",
" except Exception:\n",
" link = \"リンク取得エラー\"\n",
"\n",
" all_results.append([trial_id, title, condition, status, date, link])\n",
"\n",
" # ページネーションの確認\n",
" try:\n",
" current_page = driver.find_element(By.CSS_SELECTOR, \"ul.pagination li.active\").text\n",
" print(f\"{current_page} ページ目を処理しました。\")\n",
" except Exception:\n",
" print(\"ページネーションが存在しません。全ての結果を取得しました。\")\n",
" break\n",
"\n",
" # 次ページボタンのリストを取得\n",
" pagination_buttons = driver.find_elements(By.CSS_SELECTOR, \"ul.pagination li a\")\n",
" next_button = None\n",
" for button in pagination_buttons:\n",
" if button.text.isdigit() and int(button.text) > int(current_page):\n",
" next_button = button\n",
" break\n",
"\n",
" if next_button:\n",
" try:\n",
" driver.execute_script(\"arguments[0].scrollIntoView();\", next_button) # ボタンを画面内にスクロール\n",
" WebDriverWait(driver, 10).until(EC.element_to_be_clickable((By.LINK_TEXT, next_button.text))).click()\n",
" except ElementClickInterceptedException:\n",
" print(\"次ページボタンがクリックできないため、JavaScriptでクリックします。\")\n",
" driver.execute_script(\"arguments[0].click();\", next_button)\n",
" WebDriverWait(driver, 10).until(EC.staleness_of(rows[0])) # ページが変わるまで待機\n",
" else:\n",
" print(\"次のページはありません。全ての結果を取得しました。\")\n",
" break\n",
"\n",
" finally:\n",
" # ブラウザを閉じる\n",
" driver.quit()\n",
"\n",
" return all_results\n"
]
},
{
"cell_type": "code",
"execution_count": 14,
"metadata": {},
"outputs": [],
"source": [
"import pandas as pd\n",
"import requests\n",
"from bs4 import BeautifulSoup\n",
"\n",
"def scrape_jrct_all_details(url):\n",
" \"\"\"\n",
" 指定されたjRCT URLから必要なすべての情報を抽出します。\n",
" \"\"\"\n",
" # リクエストを送信\n",
" headers = {\n",
" \"User-Agent\": \"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/91.0.4472.124 Safari/537.36\"\n",
" }\n",
" response = requests.get(url, headers=headers)\n",
" response.raise_for_status()\n",
" soup = BeautifulSoup(response.text, 'html.parser')\n",
"\n",
" # データ格納用辞書\n",
" data = {\"URL\": url}\n",
"\n",
" # \"研究・治験の目的\" を抽出\n",
" purpose_label = soup.find('label', text='研究・治験の目的')\n",
" if purpose_label:\n",
" purpose_td = purpose_label.find_parent('th').find_next_sibling('td')\n",
" if purpose_td:\n",
" data[\"研究・治験の目的\"] = purpose_td.text.strip()\n",
"\n",
" # 試験デザイン情報（日本語と英語）を抽出\n",
" design_labels = [\n",
" ('試験の種類', 'Study Type'),\n",
" ('無作為化', 'allocation'),\n",
" ('盲検化', 'masking'),\n",
" ('対照', 'control'),\n",
" ('割付け', 'assignment'),\n",
" ('研究目的', 'purpose')\n",
" ]\n",
" for label_jp, label_en in design_labels:\n",
" label = soup.find('label', string=lambda text: text and label_jp in text)\n",
" if label:\n",
" td_jp = label.find_parent('th').find_next_sibling('td')\n",
" td_en = td_jp.find_next_sibling('td') if td_jp else None\n",
" data[label_jp] = td_jp.text.strip() if td_jp else None\n",
" data[label_en] = td_en.text.strip() if td_en else None\n",
"\n",
" # その他の情報を抽出\n",
" details_labels = [\n",
" ('主たる選択基準', 'Inclusion Criteria'),\n",
" ('主たる除外基準', 'Exclusion Criteria'),\n",
" ('年齢下限', 'Age Minimum'),\n",
" ('年齢上限', 'Age Maximum'),\n",
" ('性別', 'Gender'),\n",
" ('中止基準', 'Discontinuation Criteria'),\n",
" ('対象疾患キーワード', 'Keyword'),\n",
" ('介入の内容', 'Intervention(s)')\n",
" ]\n",
" for label_jp, label_en in details_labels:\n",
" label = soup.find('label', string=lambda text: text and label_jp in text)\n",
" if label:\n",
" td_jp = label.find_parent('th').find_next_sibling('td')\n",
" td_en = td_jp.find_next_sibling('td') if td_jp else None\n",
" data[label_jp] = (\n",
" td_jp.decode_contents().strip().replace('<br/>', '\\n') if td_jp else None\n",
" )\n",
" data[label_en] = (\n",
" td_en.decode_contents().strip().replace('<br/>', '\\n') if td_en else None\n",
" )\n",
"\n",
" return data\n",
"\n",
"def create_dataframe_from_urls(urls):\n",
" \"\"\"\n",
" URLのリストを受け取り、pandas DataFrameを作成します。\n",
" \"\"\"\n",
" all_data = []\n",
"\n",
" for url in urls:\n",
" print(f\"Processing URL: {url}\")\n",
" data = scrape_jrct_all_details(url)\n",
" all_data.append(data)\n",
"\n",
" # pandas DataFrameに変換\n",
" return pd.DataFrame(all_data)\n",
"\n",
"\n",
"def extract_jrct_links(results):\n",
" \"\"\"\n",
" fetch_clinical_trialsの結果からjRCT-Noを抽出し、詳細リンクを作成する。\n",
"\n",
" Args:\n",
" results (list): fetch_clinical_trialsから得られる結果リスト\n",
"\n",
" Returns:\n",
" list: jRCTの詳細ページリンクリスト\n",
" \"\"\"\n",
" base_url = \"https://jrct.niph.go.jp/latest-detail/\"\n",
" links = []\n",
" for result in results:\n",
" if len(result) > 0:\n",
" jrct_no = result[0] # jRCT-Noは結果リストの最初の要素\n",
" links.append(base_url + jrct_no)\n",
" return links\n",
"\n",
"def reorder_columns(df):\n",
" \"\"\"\n",
" DataFrame の列を日本語の列を前半に、英語の列を後半に並び替える。\n",
" \"\"\"\n",
" # 日本語と英語の列を分ける\n",
" jp_columns = [col for col in df.columns if all(ord(c) < 128 for c in col) is False] # 非 ASCII（日本語）文字列を含む列\n",
" en_columns = [col for col in df.columns if col not in jp_columns] # 残りの列を英語と仮定\n",
"\n",
" # 日本語列 + 英語列の順序で整列\n",
" ordered_columns = jp_columns + en_columns\n",
"\n",
" # 列を並び替えた DataFrame を返す\n",
" return df[ordered_columns]"
]
},
{
"cell_type": "code",
"execution_count": 12,
"metadata": {},
"outputs": [
{
"name": "stdout",
"output_type": "stream",
"text": [
"検索ボタンがクリックできないため、JavaScriptでクリックします。\n",
"ページネーションが存在しません。全ての結果を取得しました。\n"
]
}
],
"source": [
"# WebDriverを初期化\n",
"driver = webdriver.Chrome() # 必要に応じてChromeDriverを設定\n",
"\n",
"# fetch_clinical_trialsを使って検索結果を取得\n",
"results = fetch_clinical_trials(disease_name=\"神経膠腫 骨髄腫\", freeword=\"\")"
]
},
{
"cell_type": "code",
"execution_count": 13,
"metadata": {},
"outputs": [
{
"data": {
"text/plain": [
"[['jRCT2051240141',\n",
" '新たに診断され放射線療法を完了したH3 K27M変異を有するびまん性神経膠腫の治療のためのONC201：無作為...',\n",
" 'H3 K27M 変異を有する初発びまん性神経膠腫',\n",
" '募集中',\n",
" '令和6年11月6日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2051240121',\n",
" '放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾロミ...',\n",
" '悪性神経膠腫',\n",
" '募集中',\n",
" '令和6年9月5日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT1031240239',\n",
" 'JCOG2303: 可及的摘出されたIDH変異型星細胞腫の術後化学放射線療法に対する待機化学放射線療法の非劣性...',\n",
" '神経膠腫',\n",
" '募集中',\n",
" '令和6年7月26日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2041240056',\n",
" '[M23-001] 再発性又は難治性多発性骨髄腫患者を対象にABBV-383 を皮下投与する多施設共同，第1b 相，非...',\n",
" '多発性骨髄腫',\n",
" '募集中',\n",
" '令和6年10月3日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2021240013',\n",
" 'ノバルティスが実施した過去のサバトリマブ（MBG453）の試験を完了し，サバトリマブの継続投与によりベ...',\n",
" '多発性骨髄腫、慢性骨髄性白血病',\n",
" '募集中',\n",
" '令和6年6月27日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2031240090',\n",
" '再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医師主導治験（ST...',\n",
" '悪性神経膠腫',\n",
" '募集中',\n",
" '令和6年6月26日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2031240014',\n",
" '自家幹細胞移植に非適応又は初回治療として自家幹細胞移植を予定していない未治療の多発性骨髄腫患者を...',\n",
" '多発性骨髄腫',\n",
" '募集中',\n",
" '令和6年9月27日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2041240003',\n",
" '再発又は難治性の多発性骨髄腫患者を対象に、AZD0305を単剤療法又は抗がん剤との併用療法として投与した...',\n",
" '再発又は難治性の多発性骨髄腫',\n",
" '募集中',\n",
" '令和6年8月20日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2031230660',\n",
" '再発又は難治性多発性骨髄腫患者を対象とした，単剤療法としてのCevostamab及びCevostamab+ポマリドミド...',\n",
" '多発性骨髄腫',\n",
" '募集中',\n",
" '令和6年10月10日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2021230055',\n",
" 'CD38 を標的とする前治療を受けた再発／難治性多発性骨髄腫患者を対象とした，エルラナタマブ単剤投与と...',\n",
" '再発または難治性多発性骨髄腫',\n",
" '募集中',\n",
" '令和6年9月18日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2061230084',\n",
" '自家幹細胞移植後の奏効が不十分な初発多発性骨髄腫（NDMM）成人患者を対象とした、idecabtagene vicleu...',\n",
" '多発性骨髄腫',\n",
" '募集中',\n",
" '令和5年12月24日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2071230097',\n",
" '再発又は難治性の多発性骨髄腫（RRMM）患者を対象にMezigdomide（CC-92480）、ボルテゾミブ及びデキサメ...',\n",
" '再発又は難治性の多発性骨髄腫（RRMM）',\n",
" '募集中',\n",
" '令和6年2月20日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2071230095',\n",
" '再発又は難治性の多発性骨髄腫（RRMM）患者を対象にMezigdomide（CC-92480/BMS-986348）、カルフィルゾ...',\n",
" '多発性骨髄腫',\n",
" '募集中',\n",
" '令和6年4月9日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2011230049',\n",
" '未治療多発性骨髄腫を対象とした自家末梢血幹細胞移植後の地固め療法としてIsatuximab､Pomalidomide､Dex...',\n",
" '未治療多発性骨髄腫',\n",
" '募集中',\n",
" '令和6年11月18日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2051230108',\n",
" '再発及び難治性の多発性骨髄腫患者を対象としたBCMA x CD3 T細胞活性化抗体CC-93269の第1相オープンラベ...',\n",
" '再発及び難治性の多発性骨髄腫',\n",
" '募集中',\n",
" '令和6年1月10日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2051230069',\n",
" '神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全性と...',\n",
" '神経膠腫',\n",
" '募集中',\n",
" '令和5年9月14日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2031230223',\n",
" '新たに診断された多発性骨髄腫（NDMM）患者を対象として自家幹細胞移植（ASCT）後のiberdomide維持療法...',\n",
" '多発性骨髄腫',\n",
" '募集中',\n",
" '令和5年7月13日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2051230065',\n",
" '多発性骨髄腫患者を対象として belantamab の単剤療法と他の治療との併用療法の安全性、忍容性及び有効...',\n",
" '多発性骨髄腫',\n",
" '募集中',\n",
" '令和6年11月21日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2031230087',\n",
" '再発又は難治性の多発性骨髄腫患者を対象としたREGN5458（抗BCMA ⅹ 抗CD3二重特異性抗体）の第I/II相FIH...',\n",
" '多発性骨髄腫',\n",
" '募集中',\n",
" '令和6年6月26日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2032230060',\n",
" '初発IDH野生型低悪性度神経膠腫に対する交流電場腫瘍治療システムの有効性と安全性を検証する多施設共同...',\n",
" 'IDH野生型神経膠腫（グレードⅢ）（退形成性星細胞腫）',\n",
" '募集中',\n",
" '令和6年7月30日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT1070230005',\n",
" '迅速ウイルスPCR法によるウイルス感染症の早期診断',\n",
" '白血病、悪性リンパ腫、多発性骨髄腫、再生不良性貧血、骨髄異形成症候群',\n",
" '募集中',\n",
" '令和5年4月11日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2031230009',\n",
" '先行する第I、II及びIII相試験完了後も引き続きイサツキシマブに基づく治療によるベネフィットを得てい...',\n",
" '多発性骨髄腫',\n",
" '募集中',\n",
" '令和6年2月14日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2031230007',\n",
" 'BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医師主導治験',\n",
" '低悪性度神経膠腫、膵癌',\n",
" '募集中',\n",
" '令和6年11月22日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2041220125',\n",
" '抗CD38 モノクローナル抗体及びレナリドミドを含む1～3 ラインの前治療歴がある再発又は難治性多発性骨...',\n",
" '再発又は難治性多発性骨髄腫',\n",
" '募集中',\n",
" '令和6年10月16日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2021220036',\n",
" 'MAGNETISMM-6：移植非適応の初発多発性骨髄腫患者を対象としてエルラナタマブ（PF-06863135）とダラツム...',\n",
" '多発性骨髄腫',\n",
" '募集中',\n",
" '令和5年8月5日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2063220071',\n",
" '移植適応のある初発の多発性骨髄腫被験者を対象としたダラツムマブ，ボルテゾミブ，レナリドミド及びデ...',\n",
" '初発の多発性骨髄腫',\n",
" '募集中',\n",
" '令和6年8月29日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2021220022',\n",
" '[M22-947] 再発又は難治性多発性骨髄腫患者を対象とした薬物治療レジメンを併用したABBV-383 の用量漸増...',\n",
" '多発性骨髄腫',\n",
" '募集中',\n",
" '令和5年3月3日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2033220220',\n",
" 'Ciltacabtagene autoleucel の投与を受けた患者を対象とした長期追跡調査試験',\n",
" '多発性骨髄腫',\n",
" '募集中',\n",
" '令和5年10月21日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2031220060',\n",
" '自家造血幹細胞移植後の初発多発性骨髄腫患者を対象としてエルラナタマブ（PF 06863135）をレナリドミド...',\n",
" '移植後の初発多発性骨髄腫',\n",
" '募集中',\n",
" '令和6年9月17日',\n",
" 'リンク取得エラー'],\n",
" ['jRCTs051220019',\n",
" '再発悪性神経膠腫に対するホウ素中性子捕捉療法で生じる腫瘍局所の早期反応のPETによる探索',\n",
" '標準治療後の再発悪性神経膠腫',\n",
" '募集中',\n",
" '令和6年4月5日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2053220006',\n",
" '製品規格に適合しないIDECABTAGENE VICLEUCELを被験者に投与する拡大アクセス試験（EAP）',\n",
" '再発又は難治性の多発性骨髄腫であり，承認された添付文書に基づきide-celの投与に適格である成人被験者。',\n",
" '募集中',\n",
" '令和4年7月15日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2031210635',\n",
" '再発又は難治性多発性骨髄腫患者を対象としてteclistamabとダラツムマブ皮下投与製剤の併用（Tec-Dara）...',\n",
" '多発性骨髄腫',\n",
" '募集中',\n",
" '令和5年4月16日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2031210607',\n",
" '有効な治療法がない又は他の治療法が適さない再発・難治性多発性骨髄腫患者を対象としたベランタマブ マ...',\n",
" '多発性骨髄腫',\n",
" '募集中',\n",
" '令和4年8月5日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2033210469', 'デリタクト注使用成績比較調査', '悪性神経膠腫', '募集中', '令和6年7月9日', 'リンク取得エラー'],\n",
" ['jRCTs071210084',\n",
" '未治療の高齢多発性骨髄腫に対する新規薬剤と自家移植を組み合わせたシークエンス治療を固定期間で行う...',\n",
" '多発性骨髄腫',\n",
" '募集中',\n",
" '令和6年9月6日',\n",
" 'リンク取得エラー'],\n",
" ['jRCTs071210074',\n",
" '未治療多発性骨髄腫に対するダラツムマブ、レナリドミドおよびデキサメタゾン療法に治療奏効で層別化す...',\n",
" '多発性骨髄腫',\n",
" '募集中',\n",
" '令和6年9月3日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2031210299',\n",
" '再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験',\n",
" '再発悪性神経膠腫',\n",
" '募集中',\n",
" '令和5年1月31日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2011210025',\n",
" '造血幹細胞移植の適応とならない初発の多発性骨髄腫患者を対象として，ボルテゾミブ，レナリドミド及び...',\n",
" '多発性骨髄腫',\n",
" '募集中',\n",
" '令和5年4月7日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2051210043',\n",
" '再発又は難治性の多発性骨髄腫（RRMM）患者を対象にiberdomide、ダラツムマブ及びデキサメタゾン（IberD...',\n",
" '再発又は難治性の多発性骨髄腫（RRMM）',\n",
" '募集中',\n",
" '令和6年5月17日',\n",
" 'リンク取得エラー'],\n",
" ['jRCTs031200320',\n",
" 'JCOG1911: 高齢者または移植拒否若年者の未治療多発性骨髄腫患者に対するダラツムマブ＋メルファラン＋...',\n",
" '多発性骨髄腫',\n",
" '募集中',\n",
" '令和6年7月23日',\n",
" 'リンク取得エラー'],\n",
" ['jRCT2033200278',\n",
" 'MMG49 抗原陽性の再発・難治性多発性骨髄腫患者を対象に OPC-415 の安全性及び有効性を検討する，多施設...',\n",
" '多発性骨髄腫',\n",
" '募集中',\n",
" '令和4年11月26日',\n",
" 'リンク取得エラー'],\n",
" ['jRCTs071190010',\n",
" '悪性神経膠腫に対する高圧酸素療法、メマンチン塩酸塩併用放射線化学治療：第Ⅲ相ランダム化比較試験',\n",
" 'WHO (World Health Organization)分類2016のグレードⅢ～Ⅳに分類される悪性神経膠腫',\n",
" '募集中',\n",
" '令和6年7月11日',\n",
" 'リンク取得エラー'],\n",
" ['jRCTs021180010',\n",
" '塩酸ニムスチン(ACNU)を用いたconvection enhanced delivery法とテモゾロミド(TMZ)内服による脊髄再発神...',\n",
" '再発脊髄悪性神経膠腫',\n",
" '募集中',\n",
" '令和3年6月9日',\n",
" 'リンク取得エラー'],\n",
" ['jRCTs061180085',\n",
" '初発悪性神経膠腫に対する手術、術後放射線治療およびTemozolomide併用の標準治療と、それにWT1-W10ペプ...',\n",
" '初発悪性神経膠腫',\n",
" '募集中',\n",
" '令和3年11月25日',\n",
" 'リンク取得エラー'],\n",
" ['jRCTs031180170',\n",
" '初発悪性神経膠腫に対するVEGFR1/2ペプチドワクチンの第I/II相臨床試験',\n",
" '悪性神経膠腫',\n",
" '募集中',\n",
" '令和4年12月19日',\n",
" 'リンク取得エラー']]"
]
},
"execution_count": 13,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"results"
]
},
{
"cell_type": "code",
"execution_count": 15,
"metadata": {},
"outputs": [
{
"name": "stdout",
"output_type": "stream",
"text": [
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051240141\n"
]
},
{
"name": "stderr",
"output_type": "stream",
"text": [
"/var/folders/xj/t9whz9_x5g309fn84ql50wrm0000gn/T/ipykernel_79232/2361888799.py:21: DeprecationWarning: The 'text' argument to find()-type methods is deprecated. Use 'string' instead.\n",
" purpose_label = soup.find('label', text='研究・治験の目的')\n"
]
},
{
"name": "stdout",
"output_type": "stream",
"text": [
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051240121\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT1031240239\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2041240056\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2021240013\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031240090\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031240014\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2041240003\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031230660\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2021230055\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2061230084\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2071230097\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2071230095\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2011230049\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051230108\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051230069\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031230223\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051230065\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031230087\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2032230060\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT1070230005\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031230009\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031230007\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2041220125\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2021220036\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2063220071\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2021220022\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2033220220\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031220060\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs051220019\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2053220006\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031210635\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031210607\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2033210469\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs071210084\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs071210074\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031210299\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2011210025\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051210043\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs031200320\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2033200278\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs071190010\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs021180010\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs061180085\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs031180170\n"
]
}
],
"source": [
" # jRCT詳細リンクを作成\n",
"jrct_links = extract_jrct_links(results)\n",
"\n",
" # 詳細リンクからデータフレームを作成\n",
"df = create_dataframe_from_urls(jrct_links)"
]
},
{
"cell_type": "code",
"execution_count": 16,
"metadata": {},
"outputs": [],
"source": [
"# 整列後の DataFrame を作成\n",
"sorted_df = reorder_columns(df)"
]
},
{
"cell_type": "code",
"execution_count": 17,
"metadata": {},
"outputs": [
{
"name": "stderr",
"output_type": "stream",
"text": [
"/var/folders/xj/t9whz9_x5g309fn84ql50wrm0000gn/T/ipykernel_79232/2325933109.py:1: SettingWithCopyWarning: \n",
"A value is trying to be set on a copy of a slice from a DataFrame.\n",
"Try using .loc[row_indexer,col_indexer] = value instead\n",
"\n",
"See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
" sorted_df['JRCT ID'] = [result[0] for result in results]\n",
"/var/folders/xj/t9whz9_x5g309fn84ql50wrm0000gn/T/ipykernel_79232/2325933109.py:2: SettingWithCopyWarning: \n",
"A value is trying to be set on a copy of a slice from a DataFrame.\n",
"Try using .loc[row_indexer,col_indexer] = value instead\n",
"\n",
"See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
" sorted_df['Title'] = [result[1] for result in results]\n"
]
}
],
"source": [
"sorted_df['JRCT ID'] = [result[0] for result in results]\n",
"sorted_df['Title'] = [result[1] for result in results]"
]
},
{
"cell_type": "code",
"execution_count": 18,
"metadata": {},
"outputs": [],
"source": [
"new_order = [\"JRCT ID\", \"Title\"] + [col for col in sorted_df.columns if col not in [\"JRCT ID\", \"Title\"]]"
]
},
{
"cell_type": "code",
"execution_count": 19,
"metadata": {},
"outputs": [],
"source": [
"sorted_df = sorted_df[new_order]"
]
},
{
"cell_type": "code",
"execution_count": 20,
"metadata": {},
"outputs": [
{
"data": {
"text/html": [
"<div>\n",
"<style scoped>\n",
" .dataframe tbody tr th:only-of-type {\n",
" vertical-align: middle;\n",
" }\n",
"\n",
" .dataframe tbody tr th {\n",
" vertical-align: top;\n",
" }\n",
"\n",
" .dataframe thead th {\n",
" text-align: right;\n",
" }\n",
"</style>\n",
"<table border=\"1\" class=\"dataframe\">\n",
" <thead>\n",
" <tr style=\"text-align: right;\">\n",
" <th></th>\n",
" <th>JRCT ID</th>\n",
" <th>Title</th>\n",
" <th>研究・治験の目的</th>\n",
" <th>無作為化</th>\n",
" <th>盲検化</th>\n",
" <th>対照</th>\n",
" <th>割付け</th>\n",
" <th>研究目的</th>\n",
" <th>主たる選択基準</th>\n",
" <th>主たる除外基準</th>\n",
" <th>...</th>\n",
" <th>purpose</th>\n",
" <th>Inclusion Criteria</th>\n",
" <th>Exclusion Criteria</th>\n",
" <th>Age Minimum</th>\n",
" <th>Age Maximum</th>\n",
" <th>Gender</th>\n",
" <th>Discontinuation Criteria</th>\n",
" <th>Keyword</th>\n",
" <th>Intervention(s)</th>\n",
" <th>Study Type</th>\n",
" </tr>\n",
" </thead>\n",
" <tbody>\n",
" <tr>\n",
" <th>0</th>\n",
" <td>jRCT2051240141</td>\n",
" <td>新たに診断され放射線療法を完了したH3 K27M変異を有するびまん性神経膠腫の治療のためのO...</td>\n",
" <td>H3 K27M変異びまん性神経膠腫を有する被験者を対象に、放射線療法後に投与されたONC20...</td>\n",
" <td>無作為化比較</td>\n",
" <td>二重盲検</td>\n",
" <td>プラセボ対照</td>\n",
" <td>並行群間比較</td>\n",
" <td>治療</td>\n",
" <td>1.\\t治験の手順を理解し、（被験者又は法定代理人による）書面によるインフォームドコンセント...</td>\n",
" <td>1.\\t原発性脊椎腫瘍。\\n\\r\\n2.\\tびまん性内在性橋神経膠腫（DIPG）。DIPGは...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1. Able to understand the study procedures and...</td>\n",
" <td>1. Primary spinal tumor.\\n\\r\\n2. Diffuse intri...</td>\n",
" <td>No limit</td>\n",
" <td>No limit</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Participants will be randomized at baseline in...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>1</th>\n",
" <td>jRCT2051240121</td>\n",
" <td>放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ...</td>\n",
" <td>放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの...</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>並行群間比較</td>\n",
" <td>治療</td>\n",
" <td>以下の基準をすべて満たす必要がある<br>\\r\\n‐生検によって、以下に示す2016 年WH...</td>\n",
" <td>以下の基準のいずれかに該当する場合、本治験へ参加できない。\\n\\r\\n‐びまん性橋膠腫（di...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Subjects required to meet all the folloiwng cr...</td>\n",
" <td>Patients who meets any of the following criter...</td>\n",
" <td>No limit</td>\n",
" <td>21age old not</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Drug: Abemaciclib\\n\\r\\nAdministered orally\\n\\r...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>2</th>\n",
" <td>jRCT1031240239</td>\n",
" <td>JCOG2303: 可及的摘出されたIDH変異型星細胞腫の術後化学放射線療法に対する待機化学...</td>\n",
" <td>手術で可及的摘出（90%以上の摘出）されたIDH変異型星細胞腫Grade 3を対象に、標準治...</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>並行群間比較</td>\n",
" <td>治療</td>\n",
" <td>一次登録適格規準<br>\\r\\n(1) 登録前に実施した最新の手術時の術中迅速病理診断もしく...</td>\n",
" <td>(1) 活動性の重複がんを有する（同時性重複がん/多発がんおよび無病期間が2年以内の異時性重...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>The first registration criteria\\n\\r\\n(1) The m...</td>\n",
" <td>(1) Synchronous or metachronous (within 2 year...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Group A: Standard treatment group [Adjuvant ch...</td>\n",
" <td>Interventional</td>\n",
" </tr>\n",
" <tr>\n",
" <th>3</th>\n",
" <td>jRCT2041240056</td>\n",
" <td>[M23-001] 再発性又は難治性多発性骨髄腫患者を対象にABBV-383 を皮下投与する...</td>\n",
" <td>再発又は難治性（R/R）MMの成人患者を対象にABBV-383の安全性及び薬物動態を検討する。</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>米国東海岸がん臨床試験グループ（ECOG）のパフォーマンススコアが2以下<br>\\r\\n3～...</td>\n",
" <td>B細胞成熟抗原（BCMA）xCD3二重特異性抗体の投与歴がある。\\n</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Eastern Cooperative Oncology Group (ECOG) perf...</td>\n",
" <td>Received B-cell maturation antigen (BCMA)xCD3 ...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Experimental: ABBV-383 Dose A\\n\\r\\nParticipant...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>4</th>\n",
" <td>jRCT2021240013</td>\n",
" <td>ノバルティスが実施した過去のサバトリマブ（MBG453）の試験を完了し，サバトリマブの継続投...</td>\n",
" <td>重篤な有害事象（SAE）及び有害事象（AE）を含めて，安全性を評価すること</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>- 治験依頼者が実施するサバトリマブの試験に登録されて，サバトリマブの投与を受けており，なお...</td>\n",
" <td>- 親試験でサバトリマブの投与を受けていないコホート又は投与群の患者。\\n\\r\\n- 許容で...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Participant is currently enrolled in a Novar...</td>\n",
" <td>- Participants in cohorts or treatment groups ...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Sabatolimab (MBG453): Solution for intravenous...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>5</th>\n",
" <td>jRCT2031240090</td>\n",
" <td>再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医...</td>\n",
" <td>再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis（N4-methyl...</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>無治療対照/標準治療対照</td>\n",
" <td>並行群間比較</td>\n",
" <td>治療</td>\n",
" <td>1）\\t登録前直近の病理診断により組織学的にWHO2021に基づく悪性神経膠腫（膠芽腫または...</td>\n",
" <td>1）\\t登録前2年以内の他の悪性腫瘍の既往または合併を有する。ただし局所治療により治癒と判断...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1) Histologically diagnosed as high grade glio...</td>\n",
" <td>1) Have a history or merger of other malignanc...</td>\n",
" <td>18age old over</td>\n",
" <td>75age old under</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td>glioblastoma, grade3/4 astrocytoma, grade3 oli...</td>\n",
" <td>Group A: BPC Therapy\\n\\r\\nDepending on the pat...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>6</th>\n",
" <td>jRCT2031240014</td>\n",
" <td>自家幹細胞移植に非適応又は初回治療として自家幹細胞移植を予定していない未治療の多発性骨髄腫患...</td>\n",
" <td>本研究の目的は，teclistamabとダラツムマブ及びレナリドミドの併用（Tec-DR）並...</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>並行群間比較</td>\n",
" <td>治療</td>\n",
" <td>・国際骨髄腫作業部会（IMWG）診断規準に従って多発性骨髄腫の診断を受けている。<br>\\r...</td>\n",
" <td>・多発性骨髄腫又はくすぶり型骨髄腫に対して，短期的コルチコステロイド投与\\n\\r\\n（デキサ...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>'- Have a diagnosis of multiple myeloma accord...</td>\n",
" <td>- Received any prior therapy for multiple myel...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Teclistamab-Teclistamab, Daratumumab SC, Lenal...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>7</th>\n",
" <td>jRCT2041240003</td>\n",
" <td>再発又は難治性の多発性骨髄腫患者を対象に、AZD0305を単剤療法又は抗がん剤との併用療法と...</td>\n",
" <td>Treatment</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>- 18 歳以上又は治験が実施される管轄区域における同意の法定年齢以上の方。<br>\\n\\n...</td>\n",
" <td>- 多発性骨髄腫の中枢神経系への浸潤を示す臨床徴候が認められる方。\\n\\n\\n\\r\\n- 慢...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Participants must be at least 18 years of ag...</td>\n",
" <td>- Participants exhibiting clinical signs of ce...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>AZD0305 IV every 3 weeks\\n</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>8</th>\n",
" <td>jRCT2031230660</td>\n",
" <td>再発又は難治性多発性骨髄腫患者を対象とした，単剤療法としてのCevostamab及びCevo...</td>\n",
" <td>本試験は、再発または難治性の多発性骨髄腫（R/R MM）患者を対象に、Cevostamab単...</td>\n",
" <td>非無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>並行群間比較</td>\n",
" <td>治療</td>\n",
" <td>・過去に1回以上の前治療歴を有する、再発・難治性多発性骨髄腫患者<br>\\r\\n・Easte...</td>\n",
" <td>・治験実施計画書に規定された入院及び活動制限を遵守できない。\\n\\r\\n・同種幹細胞移植（S...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>-Participants with R/R MM who have received at...</td>\n",
" <td>-Inability to comply with protocol-mandated ho...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>cevostamab: Cevostamab will be administered in...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>9</th>\n",
" <td>jRCT2021230055</td>\n",
" <td>CD38 を標的とする前治療を受けた再発／難治性多発性骨髄腫患者を対象とした，エルラナタマブ...</td>\n",
" <td>再発または難治性多発性骨髄腫患者を対象に，エルラナタマブ単剤投与の有効性，安全性等を標準療法...</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>並行群間比較</td>\n",
" <td>治療</td>\n",
" <td>・IMWG規準で定義される多発性骨髄腫と診断を受け，過去に抗CD38抗体およびレナリドミドを...</td>\n",
" <td>・くすぶり型多発性骨髄腫を有する患者\\n\\r\\n・形質細胞白血病を有する患者\\n\\r\\n・ア...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>* Prior diagnosis of multiple myeloma as defin...</td>\n",
" <td>* Smoldering multiple myeloma.\\n\\r\\n* Plasma c...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Drug: Elranatamab\\n\\r\\nElranatamab will be adm...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>10</th>\n",
" <td>jRCT2061230084</td>\n",
" <td>自家幹細胞移植後の奏効が不十分な初発多発性骨髄腫（NDMM）成人患者を対象とした、ideca...</td>\n",
" <td>自家幹細胞移植後の奏効が不十分なNDMM成人患者を対象に、ide-cel + LEN維持療法...</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>並行群間比較</td>\n",
" <td>治療</td>\n",
" <td>・導入療法後に大量化学療法及びASCTを受けたが、その後地固め療法又は維持療法を受けていない...</td>\n",
" <td>・中枢神経系（CNS）に骨髄腫病変を有する又は既往歴のある治験参加者\\n\\r\\n・非分泌型M...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>-Participants aged &gt;=18 with Newly Diagnose...</td>\n",
" <td>-Participant with known central nervous system...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>ArmA\\n\\r\\nBiological: idecabtagene vicleucel\\n...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>11</th>\n",
" <td>jRCT2071230097</td>\n",
" <td>再発又は難治性の多発性骨髄腫（RRMM）患者を対象にMezigdomide（CC-92480...</td>\n",
" <td>再発又は難治性多発性骨髄腫（RRMM）被験者を対象にmezigdomide（CC-92480...</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>並行群間比較</td>\n",
" <td>治療</td>\n",
" <td>1. 多発性骨髄腫の診断が記録されており、以下のいずれかの定義を満たす測定可能病変を有する被...</td>\n",
" <td>1. プロテアソーム阻害剤の投与期間中又は最終投与後60日以内に病勢進行が確認された被験者。...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1. Participant has documented diagnosis of mul...</td>\n",
" <td>1. Participant has had progression during trea...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>[Japan safety lead-in cohort]\\n\\r\\nMezigdomide...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>12</th>\n",
" <td>jRCT2071230095</td>\n",
" <td>再発又は難治性の多発性骨髄腫（RRMM）患者を対象にMezigdomide（CC-92480...</td>\n",
" <td>再発又は難治性多発性骨髄腫（RRMM）治験参加者を対象にmezigdomide、カルフィルゾ...</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>多発性骨髄腫の診断が記録されており、測定可能病変を有する。<br>\\r\\n1レジメン以上の抗...</td>\n",
" <td>Mezigdomide又はカルフィルゾミブによる前治療歴を有する治験参加者。\\n\\r\\n前治...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Participant has documented diagnosis of Multip...</td>\n",
" <td>Participant who has had prior treatment with m...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Arm A: Mezigdomide, Carfilzomib and Dexamethas...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>13</th>\n",
" <td>jRCT2011230049</td>\n",
" <td>未治療多発性骨髄腫を対象とした自家末梢血幹細胞移植後の地固め療法としてIsatuximab､...</td>\n",
" <td>未治療多発性骨髄腫を対象とした自家末梢血幹細胞移植後の地固め療法としてのIsatuximab...</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>1)同意取得時の年齢が20歳以上、70歳未満の患者（性別及び入院・外来を問わず）<br>\\r...</td>\n",
" <td>1)アミロイドーシスによる症状があり、アミロイド沈着が組織学的に証明された症例\\n\\r\\n2...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1)Patients aged between 20 and less than 70 up...</td>\n",
" <td>1) Patients with symptoms due to amyloidosis a...</td>\n",
" <td>20age old over</td>\n",
" <td>70age old not</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Study treatment,Autologous Peripheral Blood St...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>14</th>\n",
" <td>jRCT2051230108</td>\n",
" <td>再発及び難治性の多発性骨髄腫患者を対象としたBCMA x CD3 T細胞活性化抗体CC-93...</td>\n",
" <td>再発及び難治性の多発性骨髄腫の被験者でのCC-93269の安全性及び忍容性を評価する。</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>・再発及び難治性の多発性骨髄腫の病歴があること。<br>\\r\\n・米国東海岸癌臨床試験グルー...</td>\n",
" <td>・症候性の中枢神経系浸潤を有する多発性骨髄腫患者\\n\\r\\n・CC-93269投与開始前3ヵ...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>-History of multiple myeloma with relapsed and...</td>\n",
" <td>-Symptomatic central nervous system involvemen...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>CC-93269</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>15</th>\n",
" <td>jRCT2051230069</td>\n",
" <td>神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...</td>\n",
" <td>神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>＜コホート1＞以下のすべての項⽬を満たすものとする。<br>\\r\\n1）摘出術⼜は⽣検の病理...</td>\n",
" <td>＜コホート1、コホート2共通＞\\n\\r\\n1） 活動性の重複がんを有する（同時性重複がん/多...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>&lt;Cohort 1&gt;\\n\\r\\n All of the following it...</td>\n",
" <td>&lt;Common to Cohort 1 and Cohort 2&gt;\\n\\r\\n1...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>&lt;cohort1&gt;\\n\\r\\nLomustine 130 mg/m2 orall...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>16</th>\n",
" <td>jRCT2031230223</td>\n",
" <td>新たに診断された多発性骨髄腫（NDMM）患者を対象として自家幹細胞移植（ASCT）後のibe...</td>\n",
" <td>新たに診断された多発性骨髄腫（NDMM）患者を対象として、自家幹細胞移植（ASCT）後のレナ...</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>並行群間比較</td>\n",
" <td>治療</td>\n",
" <td>-症候性多発性骨髄腫(MM)の確定診断を受けている<br>\\r\\n- 米国東海岸癌臨床試験グ...</td>\n",
" <td>-地固め療法の有無に関わらずASCT後にprogressive disease又は臨床的再発...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Confirmed diagnosis of symptomatic multiple ...</td>\n",
" <td>- Progressive disease or clinical relapse (as ...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Arm A1: Iberdomide Dose 1\\n\\r\\nArm A2: Iberdom...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>17</th>\n",
" <td>jRCT2051230065</td>\n",
" <td>多発性骨髄腫患者を対象として belantamab の単剤療法と他の治療との併用療法の安全性...</td>\n",
" <td>パート 1：3ライン以上の前治療を受けた（4L+）再発・難治性多発性骨髄腫（RRMM）患者を...</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>並行群間比較</td>\n",
" <td>治療</td>\n",
" <td>• 署名時の年齢が18歳以上、又は各国における同意可能な法定年齢以上である被験者。<br>\\...</td>\n",
" <td>• 原発性ALアミロイドーシス、活動性POEMS症候群、原発性形質細胞性白血病と診断されてい...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>-Participants at the time of signing the Infor...</td>\n",
" <td>- Diagnosis of primary Amyloid Light chain (AL...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Part1:\\n\\r\\nDrug: Belantamab\\n\\r\\nDrug: Belant...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>18</th>\n",
" <td>jRCT2031230087</td>\n",
" <td>再発又は難治性の多発性骨髄腫患者を対象としたREGN5458（抗BCMA ⅹ 抗CD3二重特...</td>\n",
" <td>・本治験の第I相用量漸増パート：再発又は難治性MM患者を対象に、単剤療法としてのREGN54...</td>\n",
" <td>非無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>・米国東海岸がん臨床試験グループ（ECOG）パフォーマンスステータスが1以下の被験者<br>...</td>\n",
" <td>・形質細胞白血病、原発性全身性軽鎖アミロイドーシス（骨髄腫関連アミロイドーシスを除く）、ヴァ...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Eastern Cooperative Oncology Group (ECOG) pe...</td>\n",
" <td>- Diagnosis of plasma cell leukemia, primary s...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Drug: REGN5458 administered by intravenous (IV...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>19</th>\n",
" <td>jRCT2032230060</td>\n",
" <td>初発IDH野生型低悪性度神経膠腫に対する交流電場腫瘍治療システムの有効性と安全性を検証する多...</td>\n",
" <td>初発IDH野生型低悪性度神経膠腫を対象に、放射線化学療法後のテモゾロミド維持療法期における交...</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>1）腫瘍摘出術または生検術を行い、IDH 野生型神経膠腫（グレードⅢ）（退形成性星細胞腫）＊...</td>\n",
" <td>以下のいずれかの条件に該当する者は対象としない。\\n\\r\\n1) 活動性の重複がんを有する（...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>At the time of enrollment, patients will be in...</td>\n",
" <td>Any of the following conditions shall not appl...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td>Glioma</td>\n",
" <td>The patient using the product should shave all...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>20</th>\n",
" <td>jRCT1070230005</td>\n",
" <td>迅速ウイルスPCR法によるウイルス感染症の早期診断</td>\n",
" <td>ウイルス感染疾患が疑われる患者について、検体を採取し、本診断法により①単純ヘルペスウイルス1...</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td></td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>ウイルス感染症が疑われるもの（造血幹細胞移植＜自家骨髄移植、自家末梢血幹細胞移植、同種骨髄移...</td>\n",
" <td>検体採取の同意が得られない患者、試験の担当医師が不適当と判断した患者は対象として除外する。こ...</td>\n",
" <td>...</td>\n",
" <td></td>\n",
" <td>Thing with suspected virus infection(limited t...</td>\n",
" <td>The patients who judged that the patients that...</td>\n",
" <td>No limit</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td>Leukemia, malignant lymphoma, multiple myeloma...</td>\n",
" <td></td>\n",
" <td>Observational</td>\n",
" </tr>\n",
" <tr>\n",
" <th>21</th>\n",
" <td>jRCT2031230009</td>\n",
" <td>先行する第I、II及びIII相試験完了後も引き続きイサツキシマブに基づく治療によるベネフィッ...</td>\n",
" <td>本治験は、先行する第I、II及びIII相試験完了後も引き続きイサツキシマブに基づく治療による...</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>- 同意書への署名の時点で18歳以上（又は治験を実施する管轄区域の同意の法定成人年齢以上）の...</td>\n",
" <td>以下のいずれかの基準に該当する場合は、治験の組入れ対象から除外する。\\n\\r\\n- 先行試験...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Participant must be &gt;=18 years of age (or...</td>\n",
" <td>Participants are excluded from the study if an...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Drug: Isatuximab IV (SAR650984)\\n\\r\\n Pharmace...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>22</th>\n",
" <td>jRCT2031230007</td>\n",
" <td>BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医...</td>\n",
" <td>BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫（コホート A...</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>コホートA、コホートB共通の適格規準<br>\\r\\n1）\\t保険診療下で行われているNGSを...</td>\n",
" <td>1）\\t活動性の重複がんを有する（ただし、次の①～③は除外しない：①完全切除された以下のがん...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Inclusion criteria for both cohort A and B\\n\\r...</td>\n",
" <td>1) Active double primary cancer (but not (1)-(...</td>\n",
" <td>12age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td>BRAF fusion gene, BRAF rearrangement, low-grad...</td>\n",
" <td>Binimetinib is administered 45 mg orally, twic...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>23</th>\n",
" <td>jRCT2041220125</td>\n",
" <td>抗CD38 モノクローナル抗体及びレナリドミドを含む1～3 ラインの前治療歴がある再発又は難...</td>\n",
" <td>本試験の目的は，teclistamabの有効性をPVd/Kdと比較することである。</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>並行群間比較</td>\n",
" <td>治療</td>\n",
" <td>・以下の基準により定義される多発性骨髄腫が診断されている。<br>\\r\\na. 国際骨髄腫作...</td>\n",
" <td>・B 細胞成熟抗原（BCMA）を標的とする前治療を受けていた。\\n\\r\\n・以下が認められる...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Documented diagnosis of multiple myeloma as ...</td>\n",
" <td>- Received any prior B cell maturation antigen...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Teclistamab: Participants will receive teclist...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>24</th>\n",
" <td>jRCT2021220036</td>\n",
" <td>MAGNETISMM-6：移植非適応の初発多発性骨髄腫患者を対象としてエルラナタマブ（PF-...</td>\n",
" <td>本治験のパート 1 では多発性骨髄腫（MM）患者を対象として，エルラナタマブとダラツムマブお...</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>要因分析</td>\n",
" <td>治療</td>\n",
" <td>・IMWG規準(Rajkumar et al., 2014)で定義される多発性骨髄腫と診断を...</td>\n",
" <td>・くすぶり型多発性骨髄腫\\n\\r\\n・意義不明の単クローン性免疫グロブリン血症\\n\\r\\n・...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Inclusion Criteria:\\n\\r\\n*Diagnosis of multipl...</td>\n",
" <td>Exclusion Criteria:\\n\\r\\n*Smoldering Multiple ...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Part 1 Dose Level 1:Elranatamab, Daratumumab, ...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>25</th>\n",
" <td>jRCT2063220071</td>\n",
" <td>移植適応のある初発の多発性骨髄腫被験者を対象としたダラツムマブ，ボルテゾミブ，レナリドミド及...</td>\n",
" <td>無増悪生存期間（PFS）及び持続的微小残存病変（MRD）陰性complete respons...</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>並行群間比較</td>\n",
" <td>治療</td>\n",
" <td>・IMWGの診断基準に従いNDMMと確定診断されており，初期治療計画の一部として大量療法及び...</td>\n",
" <td>・標的を問わずCAR-T療法による前治療。\\n\\r\\n・BCMAを標的とする全ての治療歴。\\...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Participants with documented NDMM accordin...</td>\n",
" <td>- Prior treatment with CAR-T therapy directed ...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>- Arm A (DVRd Induction + ASCT + DVRd Consolid...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>26</th>\n",
" <td>jRCT2021220022</td>\n",
" <td>[M22-947] 再発又は難治性多発性骨髄腫患者を対象とした薬物治療レジメンを併用したAB...</td>\n",
" <td>再発又は難治性多発性骨髄腫患者を対象にポマリドミド-デキサメタソン（Pd），レナリドミド-デ...</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>- 米国東海岸がん臨床試験グループ（ECOG）performanceが2以下である。<br>...</td>\n",
" <td>- 治験薬の初回投与前12 週間以内に末梢血自家幹細胞移植を受けている，又は治験薬の初回投与...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Eastern Cooperative Oncology Group (ECOG) pe...</td>\n",
" <td>- Received a peripheral autologous stem cell t...</td>\n",
" <td>20age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Participants will receive intravenous (IV) ABB...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>27</th>\n",
" <td>jRCT2033220220</td>\n",
" <td>Ciltacabtagene autoleucel の投与を受けた患者を対象とした長期追跡調査試験</td>\n",
" <td>この試験の目的は、ciltacabtagene autoleucel(Cilta-cel)投...</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>その他</td>\n",
" <td>・企業が主導（共同）して実施する臨床試験でcilta-celの投与を少なくとも1回受けた被験...</td>\n",
" <td>なし</td>\n",
" <td>...</td>\n",
" <td>other</td>\n",
" <td>- Participants who have received at least one ...</td>\n",
" <td>N/A</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Cilta-cel:Participants who had received cilta-...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>28</th>\n",
" <td>jRCT2031220060</td>\n",
" <td>自家造血幹細胞移植後の初発多発性骨髄腫患者を対象としてエルラナタマブ（PF 06863135...</td>\n",
" <td>自家造血幹細胞移植後に初発多発性骨髄腫患者を対象として，PF-06863135の単剤投与がレ...</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>並行群間比較</td>\n",
" <td>治療</td>\n",
" <td>選択基準:<br>\\r\\n•IMWG 規準で定義される多発性骨髄腫と診断を受けた患者。初発多...</td>\n",
" <td>除外基準:\\n\\r\\n•形質細胞白血病\\n\\r\\n•アミロイドーシス，ワルデンシュトレームマ...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Inclusion Criteria:\\n\\r\\n*Diagnosis of MM as d...</td>\n",
" <td>Exclusion Criteria:\\n\\r\\n*Plasma cell leukemia...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Drug: Elranatamab \\n\\r\\nBCMA-CD3 bispecific an...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>29</th>\n",
" <td>jRCTs051220019</td>\n",
" <td>再発悪性神経膠腫に対するホウ素中性子捕捉療法で生じる腫瘍局所の早期反応のPETによる探索</td>\n",
" <td>BNCT(Boron Neutron Capture Therapy：ホウ素中性子捕捉療法)...</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>その他</td>\n",
" <td>① 悪性神経膠腫の病理組織学的診断が得られている。<br>\\r\\n② 標準治療後に再発し、ベ...</td>\n",
" <td>① 髄腔播種を認める。\\n\\r\\n② 抗生物質、抗ウイルス薬、抗真菌薬などの静脈内投与が必要...</td>\n",
" <td>...</td>\n",
" <td>other</td>\n",
" <td>1. A histopathological diagnosis of malignant ...</td>\n",
" <td>Patients with the following medical conditions...</td>\n",
" <td>20age 0month 0week old over</td>\n",
" <td>79age 0month 0week old under</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>BNCT is performed in combination with a cyclot...</td>\n",
" <td>Interventional</td>\n",
" </tr>\n",
" <tr>\n",
" <th>30</th>\n",
" <td>jRCT2053220006</td>\n",
" <td>製品規格に適合しないIDECABTAGENE VICLEUCELを被験者に投与する拡大アクセ...</td>\n",
" <td>本治験の主要目的は、不適合ide-celの安全性を評価することである。</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>1.治験開始前に、同意説明文書の内容を理解し、自由意思により署名できる被験者及び／又はLAR...</td>\n",
" <td>1.有効成分又は添加剤に対して過敏症のある患者。\\n\\r\\n2.担当医師の判断で、LD化学療...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1.Subject and/or LAR must understand and volun...</td>\n",
" <td>1. Subject has a hypersensitivity to the activ...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>In accordance with the ide-cel prescribing inf...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>31</th>\n",
" <td>jRCT2031210635</td>\n",
" <td>再発又は難治性多発性骨髄腫患者を対象としてteclistamabとダラツムマブ皮下投与製剤の...</td>\n",
" <td>本治験の目的は，teclistamab とダラツムマブ皮下投与製剤（SC）の併用（Tec-D...</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>並行群間比較</td>\n",
" <td>治療</td>\n",
" <td>選択基準<br>\\r\\n‐以下の基準により定義される多発性骨髄腫が確認されている。\\n\\r\\...</td>\n",
" <td>除外基準\\n\\r\\n‐治験薬又はその添加物に対する禁忌又は生命を脅かすアレルギー，過敏症を呈...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Inclusion Criteria:\\n\\r\\n- Documented multiple...</td>\n",
" <td>Exclusion Criteria:\\n\\r\\n- Contraindications o...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Daratumumab\\n\\r\\nArm A: Teclistamab-daratumuma...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>32</th>\n",
" <td>jRCT2031210607</td>\n",
" <td>有効な治療法がない又は他の治療法が適さない再発・難治性多発性骨髄腫患者を対象としたベランタマ...</td>\n",
" <td>既存の治療法でベネフィットが得られず、進行中又は実施予定の本剤の臨床試験に適格でなく、かつ適...</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>-国際骨髄腫作業部会(IMWG)の基準[Rajkumar, 2014]に従って組織学的又は細...</td>\n",
" <td>-同種幹細胞移植歴を有する被験者\\n\\r\\n-腎疾患、肝疾患、心血管障害、悪性腫瘍を含む、重...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>-Histologically or cytologically confirmed dia...</td>\n",
" <td>-Prior allogenic stem cell transplant.\\n\\r\\n-A...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Belantamab mafodotin (anti-BCMA (B-cell matura...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>33</th>\n",
" <td>jRCT2033210469</td>\n",
" <td>デリタクト注使用成績比較調査</td>\n",
" <td>使用実態下におけるデリタクト注の悪性神経膠腫患者に対する安全性及び有効性を確認することを目的...</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td></td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>・本品投与群：登録期間内に本剤の投与を開始する全ての患者<br>\\r\\n・対照群：本品納入施...</td>\n",
" <td>なし</td>\n",
" <td>...</td>\n",
" <td></td>\n",
" <td>-Delytact injection group : All patients who s...</td>\n",
" <td>none</td>\n",
" <td>No limit</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>34</th>\n",
" <td>jRCTs071210084</td>\n",
" <td>未治療の高齢多発性骨髄腫に対する新規薬剤と自家移植を組み合わせたシークエンス治療を固定期間で...</td>\n",
" <td>未治療の高齢者多発性骨髄腫に対する新規薬剤と自家移植を組み合わせたシークエンス治療を固定期間...</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>1) 登録時の年齢が66歳以上75歳以下で、fitの患者。<br>\\r\\n2) IMWG...</td>\n",
" <td>1) くすぶり型およびIgM型の骨髄腫、孤立性形質細胞腫、形質細胞性白血病、POEMS症候...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1) Patients who are 66 years old or older and ...</td>\n",
" <td>1) Cases of smoldering and IgM myeloma, solita...</td>\n",
" <td>66age old over</td>\n",
" <td>75age old under</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>1. Daratumumab + lenalidomide + dexamethasone ...</td>\n",
" <td>Interventional</td>\n",
" </tr>\n",
" <tr>\n",
" <th>35</th>\n",
" <td>jRCTs071210074</td>\n",
" <td>未治療多発性骨髄腫に対するダラツムマブ、レナリドミドおよびデキサメタゾン療法に治療奏効で層別...</td>\n",
" <td>未治療多発性骨髄腫に対し、ダラツムマブ、レナリドミドおよびデキサメサゾン投与による寛解導入療...</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>1) 登録時の年齢が20歳以上65歳以下の症例。<br>\\r\\n2) IMWGの診断基準...</td>\n",
" <td>1) くすぶり型およびIgM型の骨髄腫、孤立性形質細胞腫、形質細胞性白血病、POEMS症候...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1) Cases in which the age at the time of regis...</td>\n",
" <td>1) Cases of smoldering and IgM myeloma, solita...</td>\n",
" <td>20age old over</td>\n",
" <td>65age old under</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>1) Induction therapy\\n\\r\\nDRD therapy 1,2 cour...</td>\n",
" <td>Interventional</td>\n",
" </tr>\n",
" <tr>\n",
" <th>36</th>\n",
" <td>jRCT2031210299</td>\n",
" <td>再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験</td>\n",
" <td>再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び...</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>1.\\t3ヵ月以上の生存が見込める患者<br>\\r\\n2.\\t前治療（化学療法、手術又は放射...</td>\n",
" <td>1.\\tDay 1前の3ヵ月以内にベバシズマブ又はその他の血管内皮増殖因子（VEGF）阻害薬...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1.\\tEstimated life expectancy &gt;= 3 months\\n...</td>\n",
" <td>1.\\tPrior therapy with bevacizumab or other an...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Patients will receive DSP-0390 orally once dai...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>37</th>\n",
" <td>jRCT2011210025</td>\n",
" <td>造血幹細胞移植の適応とならない初発の多発性骨髄腫患者を対象として，ボルテゾミブ，レナリドミド...</td>\n",
" <td>造血幹細胞移植が適応とならない初発の多発性骨髄腫患者において，VRd 導入療法後にJNJ-6...</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>並行群間比較</td>\n",
" <td>治療</td>\n",
" <td>･国際骨髄腫作業部会(IMWG )診断規準によるMMの診断が確定している被験者。<br>\\r...</td>\n",
" <td>･Myeloma Geriatric Assessmentスコアに従ったフレイル指数が2点以...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Documented diagnosis of multiple myeloma (MM...</td>\n",
" <td>-Frailty index of &gt;=2 according to Myeloma ...</td>\n",
" <td>20age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Arm A\\n\\r\\nParticipants will receive bortezomi...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>38</th>\n",
" <td>jRCT2051210043</td>\n",
" <td>再発又は難治性の多発性骨髄腫（RRMM）患者を対象にiberdomide、ダラツムマブ及びデ...</td>\n",
" <td>再発又は難治性の多発性骨髄腫（RRMM）患者を対象に無増悪生存期間（PFS）についてiber...</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>並行群間比較</td>\n",
" <td>治療</td>\n",
" <td>1. MMの診断がされており測定可能病変（以下の基準のいずれかに該当する場合と定義）を有する...</td>\n",
" <td>1. 以下の臨床検査値異常のいずれかが認められる\\n\\r\\na. 好中球絶対数（ANC）が1...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1. Documented diagnosis of MM and measurable d...</td>\n",
" <td>1. Any of the following laboratory abnormaliti...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>[IberDd] At the First Stage, Iberdomide (CC-22...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>39</th>\n",
" <td>jRCTs031200320</td>\n",
" <td>JCOG1911: 高齢者または移植拒否若年者の未治療多発性骨髄腫患者に対するダラツムマブ＋...</td>\n",
" <td>高齢または移植拒否若年の未治療多発性骨髄腫患者に対するダラツムマブ＋メルファラン＋プレドニゾ...</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>並行群間比較</td>\n",
" <td>治療</td>\n",
" <td>一次登録適格規準<br>\\r\\n（1）IMWG2014の診断規準のMyeloma defin...</td>\n",
" <td>（1）活動性の重複がんを有する（同時性重複がん/多発がんおよび無病期間が5年以内の異時性重複...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>First registration criteria\\n\\r\\n(1)At leaset ...</td>\n",
" <td>(1) Simultaneous or metachronous (within 5 yea...</td>\n",
" <td>20age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Induction therapy (both arm A and arm B) D-MPB...</td>\n",
" <td>Interventional</td>\n",
" </tr>\n",
" <tr>\n",
" <th>40</th>\n",
" <td>jRCT2033200278</td>\n",
" <td>MMG49 抗原陽性の再発・難治性多発性骨髄腫患者を対象に OPC-415 の安全性及び有効...</td>\n",
" <td>【第 I 相部分】\\r\\n• 骨髄腫細胞特異的抗体（ MMG49）抗原陽性の再発・難治性のM...</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>-同意取得時の年齢が20歳以上，80歳（第 I 相部分では75歳）以下の患者<br>\\r\\n...</td>\n",
" <td>-次治療で造血幹細胞移植併用大量化学療法を予定している患者\\n\\r\\n-他の活動性の重複がん...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>-Patients aged between 20 and 80 (75 for the p...</td>\n",
" <td>-Patients who are scheduled to receive high-do...</td>\n",
" <td>20age old over</td>\n",
" <td>80age old under</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>OPC-415 (up to 1X10^7cells/kg)\\n\\r\\nOn 2 days\\...</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>41</th>\n",
" <td>jRCTs071190010</td>\n",
" <td>悪性神経膠腫に対する高圧酸素療法、メマンチン塩酸塩併用放射線化学治療：第Ⅲ相ランダム化比較試験</td>\n",
" <td>悪性神経膠腫患者に対する放射線照射療法によって引き起こされる認知機能低下が、メマンチン塩酸塩...</td>\n",
" <td>無作為化比較</td>\n",
" <td>二重盲検</td>\n",
" <td>プラセボ対照</td>\n",
" <td>並行群間比較</td>\n",
" <td>治療</td>\n",
" <td>1. 神経放射線学的及び病理組織学的診断法を用いWHO (World Health Orga...</td>\n",
" <td>1．試験薬に対して過敏症のある患者\\n\\r\\n2．腎機能障害のある患者\\n\\r\\n3．尿pH...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Patients with malignant glioma who are classif...</td>\n",
" <td>1. Patients with hypersensitivity to the study...</td>\n",
" <td>20age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td>gliobalastoma, anaplastic astrocytoma,anaplast...</td>\n",
" <td>1)Arm A: Patients randomly selected group have...</td>\n",
" <td>Interventional</td>\n",
" </tr>\n",
" <tr>\n",
" <th>42</th>\n",
" <td>jRCTs021180010</td>\n",
" <td>塩酸ニムスチン(ACNU)を用いたconvection enhanced delivery法...</td>\n",
" <td>悪性脊髄神経膠腫に対する塩酸ニムスチンを用いたconvection enhanced del...</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>無治療対照/標準治療対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>1.\\t臨床的に脊髄再発神経膠腫と考えられる症例。放射線画像診断的には、脊髄髄内に病変を有す...</td>\n",
" <td>1)\\t活動性の重複がんを有する\\n\\r\\n2)\\t治療が必要な髄膜炎または肺炎を合併\\n\\...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1. Clinically considered a spinal cord recurre...</td>\n",
" <td>1) have active duplicate cancer\\n\\r\\n2) Mergin...</td>\n",
" <td>15age old over</td>\n",
" <td>75age old under</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td>Spinal cord tumor</td>\n",
" <td>ACNU delivery (0.25 mg/ml, 4ml) into the spin...</td>\n",
" <td>Interventional</td>\n",
" </tr>\n",
" <tr>\n",
" <th>43</th>\n",
" <td>jRCTs061180085</td>\n",
" <td>初発悪性神経膠腫に対する手術、術後放射線治療およびTemozolomide併用の標準治療と、...</td>\n",
" <td>初発悪性神経膠腫において手術、放射線治療およびTemozolomideを受ける、化学療法未施...</td>\n",
" <td>非無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>悪性神経膠腫において、これから放射線療法を受ける、化学療法未施行症例に対し、WT1-W10ペ...</td>\n",
" <td>1）コントロール不良な感染症（活動性の結核を含む）を有する患者。\\n\\r\\n2）重篤な合併症...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Malignant glioma patients who are going to rec...</td>\n",
" <td>1)\\tPatients with uncontrollable infectious di...</td>\n",
" <td>18age old over</td>\n",
" <td>80age old not</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>1)\\tWT1-W10 peptide immunotherapy\\n\\r\\nIntrade...</td>\n",
" <td>Interventional</td>\n",
" </tr>\n",
" <tr>\n",
" <th>44</th>\n",
" <td>jRCTs031180170</td>\n",
" <td>初発悪性神経膠腫に対するVEGFR1/2ペプチドワクチンの第I/II相臨床試験</td>\n",
" <td>初発悪性神経膠腫に対するVEGFR1/2由来のHLA-A*2402拘束性エピトープペプチドを...</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>ヒストリカルコントロール</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>1）悪性神経膠腫 <br>\\r\\n2）HLA型がHLA-A*2402、A*0201、A*02...</td>\n",
" <td>1)コントロール不良な感染症を有する患者。 \\n\\r\\n2）重篤な合併症を有する患者。 \\n...</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1)malignant glioma \\n\\r\\n2) HLA-A*2402, A*0201...</td>\n",
" <td>1) Uncontrollable severe infectious diseases. ...</td>\n",
" <td>16age old over</td>\n",
" <td>79age old under</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td>Malignant glioma</td>\n",
" <td>Subcutaneous injection of VEGFR1 and VEGFR2 pe...</td>\n",
" <td>Interventional</td>\n",
" </tr>\n",
" </tbody>\n",
"</table>\n",
"<p>45 rows × 32 columns</p>\n",
"</div>"
],
"text/plain": [
" JRCT ID Title \\\n",
"0 jRCT2051240141 新たに診断され放射線療法を完了したH3 K27M変異を有するびまん性神経膠腫の治療のためのO... \n",
"1 jRCT2051240121 放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ... \n",
"2 jRCT1031240239 JCOG2303: 可及的摘出されたIDH変異型星細胞腫の術後化学放射線療法に対する待機化学... \n",
"3 jRCT2041240056 [M23-001] 再発性又は難治性多発性骨髄腫患者を対象にABBV-383 を皮下投与する... \n",
"4 jRCT2021240013 ノバルティスが実施した過去のサバトリマブ（MBG453）の試験を完了し，サバトリマブの継続投... \n",
"5 jRCT2031240090 再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医... \n",
"6 jRCT2031240014 自家幹細胞移植に非適応又は初回治療として自家幹細胞移植を予定していない未治療の多発性骨髄腫患... \n",
"7 jRCT2041240003 再発又は難治性の多発性骨髄腫患者を対象に、AZD0305を単剤療法又は抗がん剤との併用療法と... \n",
"8 jRCT2031230660 再発又は難治性多発性骨髄腫患者を対象とした，単剤療法としてのCevostamab及びCevo... \n",
"9 jRCT2021230055 CD38 を標的とする前治療を受けた再発／難治性多発性骨髄腫患者を対象とした，エルラナタマブ... \n",
"10 jRCT2061230084 自家幹細胞移植後の奏効が不十分な初発多発性骨髄腫（NDMM）成人患者を対象とした、ideca... \n",
"11 jRCT2071230097 再発又は難治性の多発性骨髄腫（RRMM）患者を対象にMezigdomide（CC-92480... \n",
"12 jRCT2071230095 再発又は難治性の多発性骨髄腫（RRMM）患者を対象にMezigdomide（CC-92480... \n",
"13 jRCT2011230049 未治療多発性骨髄腫を対象とした自家末梢血幹細胞移植後の地固め療法としてIsatuximab､... \n",
"14 jRCT2051230108 再発及び難治性の多発性骨髄腫患者を対象としたBCMA x CD3 T細胞活性化抗体CC-93... \n",
"15 jRCT2051230069 神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... \n",
"16 jRCT2031230223 新たに診断された多発性骨髄腫（NDMM）患者を対象として自家幹細胞移植（ASCT）後のibe... \n",
"17 jRCT2051230065 多発性骨髄腫患者を対象として belantamab の単剤療法と他の治療との併用療法の安全性... \n",
"18 jRCT2031230087 再発又は難治性の多発性骨髄腫患者を対象としたREGN5458（抗BCMA ⅹ 抗CD3二重特... \n",
"19 jRCT2032230060 初発IDH野生型低悪性度神経膠腫に対する交流電場腫瘍治療システムの有効性と安全性を検証する多... \n",
"20 jRCT1070230005 迅速ウイルスPCR法によるウイルス感染症の早期診断 \n",
"21 jRCT2031230009 先行する第I、II及びIII相試験完了後も引き続きイサツキシマブに基づく治療によるベネフィッ... \n",
"22 jRCT2031230007 BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医... \n",
"23 jRCT2041220125 抗CD38 モノクローナル抗体及びレナリドミドを含む1～3 ラインの前治療歴がある再発又は難... \n",
"24 jRCT2021220036 MAGNETISMM-6：移植非適応の初発多発性骨髄腫患者を対象としてエルラナタマブ（PF-... \n",
"25 jRCT2063220071 移植適応のある初発の多発性骨髄腫被験者を対象としたダラツムマブ，ボルテゾミブ，レナリドミド及... \n",
"26 jRCT2021220022 [M22-947] 再発又は難治性多発性骨髄腫患者を対象とした薬物治療レジメンを併用したAB... \n",
"27 jRCT2033220220 Ciltacabtagene autoleucel の投与を受けた患者を対象とした長期追跡調査試験 \n",
"28 jRCT2031220060 自家造血幹細胞移植後の初発多発性骨髄腫患者を対象としてエルラナタマブ（PF 06863135... \n",
"29 jRCTs051220019 再発悪性神経膠腫に対するホウ素中性子捕捉療法で生じる腫瘍局所の早期反応のPETによる探索 \n",
"30 jRCT2053220006 製品規格に適合しないIDECABTAGENE VICLEUCELを被験者に投与する拡大アクセ... \n",
"31 jRCT2031210635 再発又は難治性多発性骨髄腫患者を対象としてteclistamabとダラツムマブ皮下投与製剤の... \n",
"32 jRCT2031210607 有効な治療法がない又は他の治療法が適さない再発・難治性多発性骨髄腫患者を対象としたベランタマ... \n",
"33 jRCT2033210469 デリタクト注使用成績比較調査 \n",
"34 jRCTs071210084 未治療の高齢多発性骨髄腫に対する新規薬剤と自家移植を組み合わせたシークエンス治療を固定期間で... \n",
"35 jRCTs071210074 未治療多発性骨髄腫に対するダラツムマブ、レナリドミドおよびデキサメタゾン療法に治療奏効で層別... \n",
"36 jRCT2031210299 再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験 \n",
"37 jRCT2011210025 造血幹細胞移植の適応とならない初発の多発性骨髄腫患者を対象として，ボルテゾミブ，レナリドミド... \n",
"38 jRCT2051210043 再発又は難治性の多発性骨髄腫（RRMM）患者を対象にiberdomide、ダラツムマブ及びデ... \n",
"39 jRCTs031200320 JCOG1911: 高齢者または移植拒否若年者の未治療多発性骨髄腫患者に対するダラツムマブ＋... \n",
"40 jRCT2033200278 MMG49 抗原陽性の再発・難治性多発性骨髄腫患者を対象に OPC-415 の安全性及び有効... \n",
"41 jRCTs071190010 悪性神経膠腫に対する高圧酸素療法、メマンチン塩酸塩併用放射線化学治療：第Ⅲ相ランダム化比較試験 \n",
"42 jRCTs021180010 塩酸ニムスチン(ACNU)を用いたconvection enhanced delivery法... \n",
"43 jRCTs061180085 初発悪性神経膠腫に対する手術、術後放射線治療およびTemozolomide併用の標準治療と、... \n",
"44 jRCTs031180170 初発悪性神経膠腫に対するVEGFR1/2ペプチドワクチンの第I/II相臨床試験 \n",
"\n",
" 研究・治験の目的 無作為化 盲検化 \\\n",
"0 H3 K27M変異びまん性神経膠腫を有する被験者を対象に、放射線療法後に投与されたONC20... 無作為化比較 二重盲検 \n",
"1 放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの... 無作為化比較 非盲検 \n",
"2 手術で可及的摘出（90%以上の摘出）されたIDH変異型星細胞腫Grade 3を対象に、標準治... 無作為化比較 非盲検 \n",
"3 再発又は難治性（R/R）MMの成人患者を対象にABBV-383の安全性及び薬物動態を検討する。 単一群 非盲検 \n",
"4 重篤な有害事象（SAE）及び有害事象（AE）を含めて，安全性を評価すること 単一群 非盲検 \n",
"5 再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis（N4-methyl... 無作為化比較 非盲検 \n",
"6 本研究の目的は，teclistamabとダラツムマブ及びレナリドミドの併用（Tec-DR）並... 無作為化比較 非盲検 \n",
"7 Treatment 単一群 非盲検 \n",
"8 本試験は、再発または難治性の多発性骨髄腫（R/R MM）患者を対象に、Cevostamab単... 非無作為化比較 非盲検 \n",
"9 再発または難治性多発性骨髄腫患者を対象に，エルラナタマブ単剤投与の有効性，安全性等を標準療法... 無作為化比較 非盲検 \n",
"10 自家幹細胞移植後の奏効が不十分なNDMM成人患者を対象に、ide-cel + LEN維持療法... 無作為化比較 非盲検 \n",
"11 再発又は難治性多発性骨髄腫（RRMM）被験者を対象にmezigdomide（CC-92480... 無作為化比較 非盲検 \n",
"12 再発又は難治性多発性骨髄腫（RRMM）治験参加者を対象にmezigdomide、カルフィルゾ... 無作為化比較 非盲検 \n",
"13 未治療多発性骨髄腫を対象とした自家末梢血幹細胞移植後の地固め療法としてのIsatuximab... 単一群 非盲検 \n",
"14 再発及び難治性の多発性骨髄腫の被験者でのCC-93269の安全性及び忍容性を評価する。 単一群 非盲検 \n",
"15 神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... 単一群 非盲検 \n",
"16 新たに診断された多発性骨髄腫（NDMM）患者を対象として、自家幹細胞移植（ASCT）後のレナ... 無作為化比較 非盲検 \n",
"17 パート 1：3ライン以上の前治療を受けた（4L+）再発・難治性多発性骨髄腫（RRMM）患者を... 無作為化比較 非盲検 \n",
"18 ・本治験の第I相用量漸増パート：再発又は難治性MM患者を対象に、単剤療法としてのREGN54... 非無作為化比較 非盲検 \n",
"19 初発IDH野生型低悪性度神経膠腫を対象に、放射線化学療法後のテモゾロミド維持療法期における交... 単一群 非盲検 \n",
"20 ウイルス感染疾患が疑われる患者について、検体を採取し、本診断法により①単純ヘルペスウイルス1... \n",
"21 本治験は、先行する第I、II及びIII相試験完了後も引き続きイサツキシマブに基づく治療による... 単一群 非盲検 \n",
"22 BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫（コホート A... 単一群 非盲検 \n",
"23 本試験の目的は，teclistamabの有効性をPVd/Kdと比較することである。 無作為化比較 非盲検 \n",
"24 本治験のパート 1 では多発性骨髄腫（MM）患者を対象として，エルラナタマブとダラツムマブお... 無作為化比較 非盲検 \n",
"25 無増悪生存期間（PFS）及び持続的微小残存病変（MRD）陰性complete respons... 無作為化比較 非盲検 \n",
"26 再発又は難治性多発性骨髄腫患者を対象にポマリドミド-デキサメタソン（Pd），レナリドミド-デ... 単一群 非盲検 \n",
"27 この試験の目的は、ciltacabtagene autoleucel(Cilta-cel)投... 単一群 非盲検 \n",
"28 自家造血幹細胞移植後に初発多発性骨髄腫患者を対象として，PF-06863135の単剤投与がレ... 無作為化比較 非盲検 \n",
"29 BNCT(Boron Neutron Capture Therapy：ホウ素中性子捕捉療法)... 単一群 非盲検 \n",
"30 本治験の主要目的は、不適合ide-celの安全性を評価することである。 単一群 非盲検 \n",
"31 本治験の目的は，teclistamab とダラツムマブ皮下投与製剤（SC）の併用（Tec-D... 無作為化比較 非盲検 \n",
"32 既存の治療法でベネフィットが得られず、進行中又は実施予定の本剤の臨床試験に適格でなく、かつ適... 単一群 非盲検 \n",
"33 使用実態下におけるデリタクト注の悪性神経膠腫患者に対する安全性及び有効性を確認することを目的... \n",
"34 未治療の高齢者多発性骨髄腫に対する新規薬剤と自家移植を組み合わせたシークエンス治療を固定期間... 単一群 非盲検 \n",
"35 未治療多発性骨髄腫に対し、ダラツムマブ、レナリドミドおよびデキサメサゾン投与による寛解導入療... 単一群 非盲検 \n",
"36 再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び... 単一群 非盲検 \n",
"37 造血幹細胞移植が適応とならない初発の多発性骨髄腫患者において，VRd 導入療法後にJNJ-6... 無作為化比較 非盲検 \n",
"38 再発又は難治性の多発性骨髄腫（RRMM）患者を対象に無増悪生存期間（PFS）についてiber... 無作為化比較 非盲検 \n",
"39 高齢または移植拒否若年の未治療多発性骨髄腫患者に対するダラツムマブ＋メルファラン＋プレドニゾ... 無作為化比較 非盲検 \n",
"40 【第 I 相部分】\\r\\n• 骨髄腫細胞特異的抗体（ MMG49）抗原陽性の再発・難治性のM... 単一群 非盲検 \n",
"41 悪性神経膠腫患者に対する放射線照射療法によって引き起こされる認知機能低下が、メマンチン塩酸塩... 無作為化比較 二重盲検 \n",
"42 悪性脊髄神経膠腫に対する塩酸ニムスチンを用いたconvection enhanced del... 単一群 非盲検 \n",
"43 初発悪性神経膠腫において手術、放射線治療およびTemozolomideを受ける、化学療法未施... 非無作為化比較 非盲検 \n",
"44 初発悪性神経膠腫に対するVEGFR1/2由来のHLA-A*2402拘束性エピトープペプチドを... 単一群 非盲検 \n",
"\n",
" 対照 割付け 研究目的 \\\n",
"0 プラセボ対照 並行群間比較 治療 \n",
"1 実薬（治療）対照 並行群間比較 治療 \n",
"2 実薬（治療）対照 並行群間比較 治療 \n",
"3 非対照 単群比較 治療 \n",
"4 非対照 単群比較 治療 \n",
"5 無治療対照/標準治療対照 並行群間比較 治療 \n",
"6 実薬（治療）対照 並行群間比較 治療 \n",
"7 非対照 単群比較 治療 \n",
"8 非対照 並行群間比較 治療 \n",
"9 実薬（治療）対照 並行群間比較 治療 \n",
"10 実薬（治療）対照 並行群間比較 治療 \n",
"11 実薬（治療）対照 並行群間比較 治療 \n",
"12 実薬（治療）対照 単群比較 治療 \n",
"13 非対照 単群比較 治療 \n",
"14 非対照 単群比較 治療 \n",
"15 非対照 単群比較 治療 \n",
"16 実薬（治療）対照 並行群間比較 治療 \n",
"17 実薬（治療）対照 並行群間比較 治療 \n",
"18 非対照 単群比較 治療 \n",
"19 非対照 単群比較 治療 \n",
"20 \n",
"21 非対照 単群比較 治療 \n",
"22 非対照 単群比較 治療 \n",
"23 実薬（治療）対照 並行群間比較 治療 \n",
"24 実薬（治療）対照 要因分析 治療 \n",
"25 実薬（治療）対照 並行群間比較 治療 \n",
"26 非対照 単群比較 治療 \n",
"27 非対照 単群比較 その他 \n",
"28 実薬（治療）対照 並行群間比較 治療 \n",
"29 非対照 単群比較 その他 \n",
"30 非対照 単群比較 治療 \n",
"31 実薬（治療）対照 並行群間比較 治療 \n",
"32 非対照 単群比較 治療 \n",
"33 \n",
"34 非対照 単群比較 治療 \n",
"35 非対照 単群比較 治療 \n",
"36 非対照 単群比較 治療 \n",
"37 実薬（治療）対照 並行群間比較 治療 \n",
"38 実薬（治療）対照 並行群間比較 治療 \n",
"39 実薬（治療）対照 並行群間比較 治療 \n",
"40 非対照 単群比較 治療 \n",
"41 プラセボ対照 並行群間比較 治療 \n",
"42 無治療対照/標準治療対照 単群比較 治療 \n",
"43 非対照 単群比較 治療 \n",
"44 ヒストリカルコントロール 単群比較 治療 \n",
"\n",
" 主たる選択基準 \\\n",
"0 1.\\t治験の手順を理解し、（被験者又は法定代理人による）書面によるインフォームドコンセント... \n",
"1 以下の基準をすべて満たす必要がある<br>\\r\\n‐生検によって、以下に示す2016 年WH... \n",
"2 一次登録適格規準<br>\\r\\n(1) 登録前に実施した最新の手術時の術中迅速病理診断もしく... \n",
"3 米国東海岸がん臨床試験グループ（ECOG）のパフォーマンススコアが2以下<br>\\r\\n3～... \n",
"4 - 治験依頼者が実施するサバトリマブの試験に登録されて，サバトリマブの投与を受けており，なお... \n",
"5 1）\\t登録前直近の病理診断により組織学的にWHO2021に基づく悪性神経膠腫（膠芽腫または... \n",
"6 ・国際骨髄腫作業部会（IMWG）診断規準に従って多発性骨髄腫の診断を受けている。<br>\\r... \n",
"7 - 18 歳以上又は治験が実施される管轄区域における同意の法定年齢以上の方。<br>\\n\\n... \n",
"8 ・過去に1回以上の前治療歴を有する、再発・難治性多発性骨髄腫患者<br>\\r\\n・Easte... \n",
"9 ・IMWG規準で定義される多発性骨髄腫と診断を受け，過去に抗CD38抗体およびレナリドミドを... \n",
"10 ・導入療法後に大量化学療法及びASCTを受けたが、その後地固め療法又は維持療法を受けていない... \n",
"11 1. 多発性骨髄腫の診断が記録されており、以下のいずれかの定義を満たす測定可能病変を有する被... \n",
"12 多発性骨髄腫の診断が記録されており、測定可能病変を有する。<br>\\r\\n1レジメン以上の抗... \n",
"13 1)同意取得時の年齢が20歳以上、70歳未満の患者（性別及び入院・外来を問わず）<br>\\r... \n",
"14 ・再発及び難治性の多発性骨髄腫の病歴があること。<br>\\r\\n・米国東海岸癌臨床試験グルー... \n",
"15 ＜コホート1＞以下のすべての項⽬を満たすものとする。<br>\\r\\n1）摘出術⼜は⽣検の病理... \n",
"16 -症候性多発性骨髄腫(MM)の確定診断を受けている<br>\\r\\n- 米国東海岸癌臨床試験グ... \n",
"17 • 署名時の年齢が18歳以上、又は各国における同意可能な法定年齢以上である被験者。<br>\\... \n",
"18 ・米国東海岸がん臨床試験グループ（ECOG）パフォーマンスステータスが1以下の被験者<br>... \n",
"19 1）腫瘍摘出術または生検術を行い、IDH 野生型神経膠腫（グレードⅢ）（退形成性星細胞腫）＊... \n",
"20 ウイルス感染症が疑われるもの（造血幹細胞移植＜自家骨髄移植、自家末梢血幹細胞移植、同種骨髄移... \n",
"21 - 同意書への署名の時点で18歳以上（又は治験を実施する管轄区域の同意の法定成人年齢以上）の... \n",
"22 コホートA、コホートB共通の適格規準<br>\\r\\n1）\\t保険診療下で行われているNGSを... \n",
"23 ・以下の基準により定義される多発性骨髄腫が診断されている。<br>\\r\\na. 国際骨髄腫作... \n",
"24 ・IMWG規準(Rajkumar et al., 2014)で定義される多発性骨髄腫と診断を... \n",
"25 ・IMWGの診断基準に従いNDMMと確定診断されており，初期治療計画の一部として大量療法及び... \n",
"26 - 米国東海岸がん臨床試験グループ（ECOG）performanceが2以下である。<br>... \n",
"27 ・企業が主導（共同）して実施する臨床試験でcilta-celの投与を少なくとも1回受けた被験... \n",
"28 選択基準:<br>\\r\\n•IMWG 規準で定義される多発性骨髄腫と診断を受けた患者。初発多... \n",
"29 ① 悪性神経膠腫の病理組織学的診断が得られている。<br>\\r\\n② 標準治療後に再発し、ベ... \n",
"30 1.治験開始前に、同意説明文書の内容を理解し、自由意思により署名できる被験者及び／又はLAR... \n",
"31 選択基準<br>\\r\\n‐以下の基準により定義される多発性骨髄腫が確認されている。\\n\\r\\... \n",
"32 -国際骨髄腫作業部会(IMWG)の基準[Rajkumar, 2014]に従って組織学的又は細... \n",
"33 ・本品投与群：登録期間内に本剤の投与を開始する全ての患者<br>\\r\\n・対照群：本品納入施... \n",
"34 1) 登録時の年齢が66歳以上75歳以下で、fitの患者。<br>\\r\\n2) IMWG... \n",
"35 1) 登録時の年齢が20歳以上65歳以下の症例。<br>\\r\\n2) IMWGの診断基準... \n",
"36 1.\\t3ヵ月以上の生存が見込める患者<br>\\r\\n2.\\t前治療（化学療法、手術又は放射... \n",
"37 ･国際骨髄腫作業部会(IMWG )診断規準によるMMの診断が確定している被験者。<br>\\r... \n",
"38 1. MMの診断がされており測定可能病変（以下の基準のいずれかに該当する場合と定義）を有する... \n",
"39 一次登録適格規準<br>\\r\\n（1）IMWG2014の診断規準のMyeloma defin... \n",
"40 -同意取得時の年齢が20歳以上，80歳（第 I 相部分では75歳）以下の患者<br>\\r\\n... \n",
"41 1. 神経放射線学的及び病理組織学的診断法を用いWHO (World Health Orga... \n",
"42 1.\\t臨床的に脊髄再発神経膠腫と考えられる症例。放射線画像診断的には、脊髄髄内に病変を有す... \n",
"43 悪性神経膠腫において、これから放射線療法を受ける、化学療法未施行症例に対し、WT1-W10ペ... \n",
"44 1）悪性神経膠腫 <br>\\r\\n2）HLA型がHLA-A*2402、A*0201、A*02... \n",
"\n",
" 主たる除外基準 ... purpose \\\n",
"0 1.\\t原発性脊椎腫瘍。\\n\\r\\n2.\\tびまん性内在性橋神経膠腫（DIPG）。DIPGは... ... treatment purpose \n",
"1 以下の基準のいずれかに該当する場合、本治験へ参加できない。\\n\\r\\n‐びまん性橋膠腫（di... ... treatment purpose \n",
"2 (1) 活動性の重複がんを有する（同時性重複がん/多発がんおよび無病期間が2年以内の異時性重... ... treatment purpose \n",
"3 B細胞成熟抗原（BCMA）xCD3二重特異性抗体の投与歴がある。\\n ... treatment purpose \n",
"4 - 親試験でサバトリマブの投与を受けていないコホート又は投与群の患者。\\n\\r\\n- 許容で... ... treatment purpose \n",
"5 1）\\t登録前2年以内の他の悪性腫瘍の既往または合併を有する。ただし局所治療により治癒と判断... ... treatment purpose \n",
"6 ・多発性骨髄腫又はくすぶり型骨髄腫に対して，短期的コルチコステロイド投与\\n\\r\\n（デキサ... ... treatment purpose \n",
"7 - 多発性骨髄腫の中枢神経系への浸潤を示す臨床徴候が認められる方。\\n\\n\\n\\r\\n- 慢... ... treatment purpose \n",
"8 ・治験実施計画書に規定された入院及び活動制限を遵守できない。\\n\\r\\n・同種幹細胞移植（S... ... treatment purpose \n",
"9 ・くすぶり型多発性骨髄腫を有する患者\\n\\r\\n・形質細胞白血病を有する患者\\n\\r\\n・ア... ... treatment purpose \n",
"10 ・中枢神経系（CNS）に骨髄腫病変を有する又は既往歴のある治験参加者\\n\\r\\n・非分泌型M... ... treatment purpose \n",
"11 1. プロテアソーム阻害剤の投与期間中又は最終投与後60日以内に病勢進行が確認された被験者。... ... treatment purpose \n",
"12 Mezigdomide又はカルフィルゾミブによる前治療歴を有する治験参加者。\\n\\r\\n前治... ... treatment purpose \n",
"13 1)アミロイドーシスによる症状があり、アミロイド沈着が組織学的に証明された症例\\n\\r\\n2... ... treatment purpose \n",
"14 ・症候性の中枢神経系浸潤を有する多発性骨髄腫患者\\n\\r\\n・CC-93269投与開始前3ヵ... ... treatment purpose \n",
"15 ＜コホート1、コホート2共通＞\\n\\r\\n1） 活動性の重複がんを有する（同時性重複がん/多... ... treatment purpose \n",
"16 -地固め療法の有無に関わらずASCT後にprogressive disease又は臨床的再発... ... treatment purpose \n",
"17 • 原発性ALアミロイドーシス、活動性POEMS症候群、原発性形質細胞性白血病と診断されてい... ... treatment purpose \n",
"18 ・形質細胞白血病、原発性全身性軽鎖アミロイドーシス（骨髄腫関連アミロイドーシスを除く）、ヴァ... ... treatment purpose \n",
"19 以下のいずれかの条件に該当する者は対象としない。\\n\\r\\n1) 活動性の重複がんを有する（... ... treatment purpose \n",
"20 検体採取の同意が得られない患者、試験の担当医師が不適当と判断した患者は対象として除外する。こ... ... \n",
"21 以下のいずれかの基準に該当する場合は、治験の組入れ対象から除外する。\\n\\r\\n- 先行試験... ... treatment purpose \n",
"22 1）\\t活動性の重複がんを有する（ただし、次の①～③は除外しない：①完全切除された以下のがん... ... treatment purpose \n",
"23 ・B 細胞成熟抗原（BCMA）を標的とする前治療を受けていた。\\n\\r\\n・以下が認められる... ... treatment purpose \n",
"24 ・くすぶり型多発性骨髄腫\\n\\r\\n・意義不明の単クローン性免疫グロブリン血症\\n\\r\\n・... ... treatment purpose \n",
"25 ・標的を問わずCAR-T療法による前治療。\\n\\r\\n・BCMAを標的とする全ての治療歴。\\... ... treatment purpose \n",
"26 - 治験薬の初回投与前12 週間以内に末梢血自家幹細胞移植を受けている，又は治験薬の初回投与... ... treatment purpose \n",
"27 なし ... other \n",
"28 除外基準:\\n\\r\\n•形質細胞白血病\\n\\r\\n•アミロイドーシス，ワルデンシュトレームマ... ... treatment purpose \n",
"29 ① 髄腔播種を認める。\\n\\r\\n② 抗生物質、抗ウイルス薬、抗真菌薬などの静脈内投与が必要... ... other \n",
"30 1.有効成分又は添加剤に対して過敏症のある患者。\\n\\r\\n2.担当医師の判断で、LD化学療... ... treatment purpose \n",
"31 除外基準\\n\\r\\n‐治験薬又はその添加物に対する禁忌又は生命を脅かすアレルギー，過敏症を呈... ... treatment purpose \n",
"32 -同種幹細胞移植歴を有する被験者\\n\\r\\n-腎疾患、肝疾患、心血管障害、悪性腫瘍を含む、重... ... treatment purpose \n",
"33 なし ... \n",
"34 1) くすぶり型およびIgM型の骨髄腫、孤立性形質細胞腫、形質細胞性白血病、POEMS症候... ... treatment purpose \n",
"35 1) くすぶり型およびIgM型の骨髄腫、孤立性形質細胞腫、形質細胞性白血病、POEMS症候... ... treatment purpose \n",
"36 1.\\tDay 1前の3ヵ月以内にベバシズマブ又はその他の血管内皮増殖因子（VEGF）阻害薬... ... treatment purpose \n",
"37 ･Myeloma Geriatric Assessmentスコアに従ったフレイル指数が2点以... ... treatment purpose \n",
"38 1. 以下の臨床検査値異常のいずれかが認められる\\n\\r\\na. 好中球絶対数（ANC）が1... ... treatment purpose \n",
"39 （1）活動性の重複がんを有する（同時性重複がん/多発がんおよび無病期間が5年以内の異時性重複... ... treatment purpose \n",
"40 -次治療で造血幹細胞移植併用大量化学療法を予定している患者\\n\\r\\n-他の活動性の重複がん... ... treatment purpose \n",
"41 1．試験薬に対して過敏症のある患者\\n\\r\\n2．腎機能障害のある患者\\n\\r\\n3．尿pH... ... treatment purpose \n",
"42 1)\\t活動性の重複がんを有する\\n\\r\\n2)\\t治療が必要な髄膜炎または肺炎を合併\\n\\... ... treatment purpose \n",
"43 1）コントロール不良な感染症（活動性の結核を含む）を有する患者。\\n\\r\\n2）重篤な合併症... ... treatment purpose \n",
"44 1)コントロール不良な感染症を有する患者。 \\n\\r\\n2）重篤な合併症を有する患者。 \\n... ... treatment purpose \n",
"\n",
" Inclusion Criteria \\\n",
"0 1. Able to understand the study procedures and... \n",
"1 Subjects required to meet all the folloiwng cr... \n",
"2 The first registration criteria\\n\\r\\n(1) The m... \n",
"3 Eastern Cooperative Oncology Group (ECOG) perf... \n",
"4 - Participant is currently enrolled in a Novar... \n",
"5 1) Histologically diagnosed as high grade glio... \n",
"6 '- Have a diagnosis of multiple myeloma accord... \n",
"7 - Participants must be at least 18 years of ag... \n",
"8 -Participants with R/R MM who have received at... \n",
"9 * Prior diagnosis of multiple myeloma as defin... \n",
"10 -Participants aged >=18 with Newly Diagnose... \n",
"11 1. Participant has documented diagnosis of mul... \n",
"12 Participant has documented diagnosis of Multip... \n",
"13 1)Patients aged between 20 and less than 70 up... \n",
"14 -History of multiple myeloma with relapsed and... \n",
"15 <Cohort 1>\\n\\r\\n All of the following it... \n",
"16 - Confirmed diagnosis of symptomatic multiple ... \n",
"17 -Participants at the time of signing the Infor... \n",
"18 - Eastern Cooperative Oncology Group (ECOG) pe... \n",
"19 At the time of enrollment, patients will be in... \n",
"20 Thing with suspected virus infection(limited t... \n",
"21 - Participant must be >=18 years of age (or... \n",
"22 Inclusion criteria for both cohort A and B\\n\\r... \n",
"23 - Documented diagnosis of multiple myeloma as ... \n",
"24 Inclusion Criteria:\\n\\r\\n*Diagnosis of multipl... \n",
"25 - Participants with documented NDMM accordin... \n",
"26 - Eastern Cooperative Oncology Group (ECOG) pe... \n",
"27 - Participants who have received at least one ... \n",
"28 Inclusion Criteria:\\n\\r\\n*Diagnosis of MM as d... \n",
"29 1. A histopathological diagnosis of malignant ... \n",
"30 1.Subject and/or LAR must understand and volun... \n",
"31 Inclusion Criteria:\\n\\r\\n- Documented multiple... \n",
"32 -Histologically or cytologically confirmed dia... \n",
"33 -Delytact injection group : All patients who s... \n",
"34 1) Patients who are 66 years old or older and ... \n",
"35 1) Cases in which the age at the time of regis... \n",
"36 1.\\tEstimated life expectancy >= 3 months\\n... \n",
"37 - Documented diagnosis of multiple myeloma (MM... \n",
"38 1. Documented diagnosis of MM and measurable d... \n",
"39 First registration criteria\\n\\r\\n(1)At leaset ... \n",
"40 -Patients aged between 20 and 80 (75 for the p... \n",
"41 Patients with malignant glioma who are classif... \n",
"42 1. Clinically considered a spinal cord recurre... \n",
"43 Malignant glioma patients who are going to rec... \n",
"44 1)malignant glioma \\n\\r\\n2) HLA-A*2402, A*0201... \n",
"\n",
" Exclusion Criteria \\\n",
"0 1. Primary spinal tumor.\\n\\r\\n2. Diffuse intri... \n",
"1 Patients who meets any of the following criter... \n",
"2 (1) Synchronous or metachronous (within 2 year... \n",
"3 Received B-cell maturation antigen (BCMA)xCD3 ... \n",
"4 - Participants in cohorts or treatment groups ... \n",
"5 1) Have a history or merger of other malignanc... \n",
"6 - Received any prior therapy for multiple myel... \n",
"7 - Participants exhibiting clinical signs of ce... \n",
"8 -Inability to comply with protocol-mandated ho... \n",
"9 * Smoldering multiple myeloma.\\n\\r\\n* Plasma c... \n",
"10 -Participant with known central nervous system... \n",
"11 1. Participant has had progression during trea... \n",
"12 Participant who has had prior treatment with m... \n",
"13 1) Patients with symptoms due to amyloidosis a... \n",
"14 -Symptomatic central nervous system involvemen... \n",
"15 <Common to Cohort 1 and Cohort 2>\\n\\r\\n1... \n",
"16 - Progressive disease or clinical relapse (as ... \n",
"17 - Diagnosis of primary Amyloid Light chain (AL... \n",
"18 - Diagnosis of plasma cell leukemia, primary s... \n",
"19 Any of the following conditions shall not appl... \n",
"20 The patients who judged that the patients that... \n",
"21 Participants are excluded from the study if an... \n",
"22 1) Active double primary cancer (but not (1)-(... \n",
"23 - Received any prior B cell maturation antigen... \n",
"24 Exclusion Criteria:\\n\\r\\n*Smoldering Multiple ... \n",
"25 - Prior treatment with CAR-T therapy directed ... \n",
"26 - Received a peripheral autologous stem cell t... \n",
"27 N/A \n",
"28 Exclusion Criteria:\\n\\r\\n*Plasma cell leukemia... \n",
"29 Patients with the following medical conditions... \n",
"30 1. Subject has a hypersensitivity to the activ... \n",
"31 Exclusion Criteria:\\n\\r\\n- Contraindications o... \n",
"32 -Prior allogenic stem cell transplant.\\n\\r\\n-A... \n",
"33 none \n",
"34 1) Cases of smoldering and IgM myeloma, solita... \n",
"35 1) Cases of smoldering and IgM myeloma, solita... \n",
"36 1.\\tPrior therapy with bevacizumab or other an... \n",
"37 -Frailty index of >=2 according to Myeloma ... \n",
"38 1. Any of the following laboratory abnormaliti... \n",
"39 (1) Simultaneous or metachronous (within 5 yea... \n",
"40 -Patients who are scheduled to receive high-do... \n",
"41 1. Patients with hypersensitivity to the study... \n",
"42 1) have active duplicate cancer\\n\\r\\n2) Mergin... \n",
"43 1)\\tPatients with uncontrollable infectious di... \n",
"44 1) Uncontrollable severe infectious diseases. ... \n",
"\n",
" Age Minimum Age Maximum Gender \\\n",
"0 No limit No limit \n",
"1 No limit 21age old not \n",
"2 18age old over No limit Both \n",
"3 18age old over No limit \n",
"4 18age old over No limit Both \n",
"5 18age old over 75age old under Both \n",
"6 18age old over No limit Both \n",
"7 18age old over No limit Both \n",
"8 18age old over No limit Both \n",
"9 18age old over No limit Both \n",
"10 18age old over No limit Both \n",
"11 18age old over No limit Both \n",
"12 18age old over No limit Both \n",
"13 20age old over 70age old not Both \n",
"14 18age old over No limit Both \n",
"15 18age old over No limit Both \n",
"16 18age old over No limit Both \n",
"17 18age old over No limit Both \n",
"18 18age old over No limit Both \n",
"19 18age old over No limit Both \n",
"20 No limit No limit Both \n",
"21 18age old over No limit Both \n",
"22 12age old over No limit Both \n",
"23 18age old over No limit Both \n",
"24 18age old over No limit Both \n",
"25 18age old over No limit Both \n",
"26 20age old over No limit Both \n",
"27 18age old over No limit Both \n",
"28 18age old over No limit Both \n",
"29 20age 0month 0week old over 79age 0month 0week old under Both \n",
"30 18age old over No limit Both \n",
"31 18age old over No limit Both \n",
"32 18age old over No limit Both \n",
"33 No limit No limit Both \n",
"34 66age old over 75age old under Both \n",
"35 20age old over 65age old under Both \n",
"36 18age old over No limit Both \n",
"37 20age old over No limit Both \n",
"38 18age old over No limit Both \n",
"39 20age old over No limit Both \n",
"40 20age old over 80age old under Both \n",
"41 20age old over No limit Both \n",
"42 15age old over 75age old under Both \n",
"43 18age old over 80age old not Both \n",
"44 16age old over 79age old under Both \n",
"\n",
" Discontinuation Criteria \\\n",
"0 None \n",
"1 None \n",
"2 None \n",
"3 None \n",
"4 None \n",
"5 None \n",
"6 None \n",
"7 None \n",
"8 None \n",
"9 None \n",
"10 None \n",
"11 None \n",
"12 None \n",
"13 None \n",
"14 None \n",
"15 None \n",
"16 None \n",
"17 None \n",
"18 None \n",
"19 None \n",
"20 None \n",
"21 None \n",
"22 None \n",
"23 None \n",
"24 None \n",
"25 None \n",
"26 None \n",
"27 None \n",
"28 None \n",
"29 None \n",
"30 None \n",
"31 None \n",
"32 None \n",
"33 None \n",
"34 None \n",
"35 None \n",
"36 None \n",
"37 None \n",
"38 None \n",
"39 None \n",
"40 None \n",
"41 None \n",
"42 None \n",
"43 None \n",
"44 None \n",
"\n",
" Keyword \\\n",
"0 \n",
"1 \n",
"2 \n",
"3 \n",
"4 \n",
"5 glioblastoma, grade3/4 astrocytoma, grade3 oli... \n",
"6 \n",
"7 \n",
"8 \n",
"9 \n",
"10 \n",
"11 \n",
"12 \n",
"13 \n",
"14 \n",
"15 \n",
"16 \n",
"17 \n",
"18 \n",
"19 Glioma \n",
"20 Leukemia, malignant lymphoma, multiple myeloma... \n",
"21 \n",
"22 BRAF fusion gene, BRAF rearrangement, low-grad... \n",
"23 \n",
"24 \n",
"25 \n",
"26 \n",
"27 \n",
"28 \n",
"29 \n",
"30 \n",
"31 \n",
"32 \n",
"33 \n",
"34 \n",
"35 \n",
"36 \n",
"37 \n",
"38 \n",
"39 \n",
"40 \n",
"41 gliobalastoma, anaplastic astrocytoma,anaplast... \n",
"42 Spinal cord tumor \n",
"43 \n",
"44 Malignant glioma \n",
"\n",
" Intervention(s) Study Type \n",
"0 Participants will be randomized at baseline in... NaN \n",
"1 Drug: Abemaciclib\\n\\r\\nAdministered orally\\n\\r... NaN \n",
"2 Group A: Standard treatment group [Adjuvant ch... Interventional \n",
"3 Experimental: ABBV-383 Dose A\\n\\r\\nParticipant... NaN \n",
"4 Sabatolimab (MBG453): Solution for intravenous... NaN \n",
"5 Group A: BPC Therapy\\n\\r\\nDepending on the pat... NaN \n",
"6 Teclistamab-Teclistamab, Daratumumab SC, Lenal... NaN \n",
"7 AZD0305 IV every 3 weeks\\n NaN \n",
"8 cevostamab: Cevostamab will be administered in... NaN \n",
"9 Drug: Elranatamab\\n\\r\\nElranatamab will be adm... NaN \n",
"10 ArmA\\n\\r\\nBiological: idecabtagene vicleucel\\n... NaN \n",
"11 [Japan safety lead-in cohort]\\n\\r\\nMezigdomide... NaN \n",
"12 Arm A: Mezigdomide, Carfilzomib and Dexamethas... NaN \n",
"13 Study treatment,Autologous Peripheral Blood St... NaN \n",
"14 CC-93269 NaN \n",
"15 <cohort1>\\n\\r\\nLomustine 130 mg/m2 orall... NaN \n",
"16 Arm A1: Iberdomide Dose 1\\n\\r\\nArm A2: Iberdom... NaN \n",
"17 Part1:\\n\\r\\nDrug: Belantamab\\n\\r\\nDrug: Belant... NaN \n",
"18 Drug: REGN5458 administered by intravenous (IV... NaN \n",
"19 The patient using the product should shave all... NaN \n",
"20 Observational \n",
"21 Drug: Isatuximab IV (SAR650984)\\n\\r\\n Pharmace... NaN \n",
"22 Binimetinib is administered 45 mg orally, twic... NaN \n",
"23 Teclistamab: Participants will receive teclist... NaN \n",
"24 Part 1 Dose Level 1:Elranatamab, Daratumumab, ... NaN \n",
"25 - Arm A (DVRd Induction + ASCT + DVRd Consolid... NaN \n",
"26 Participants will receive intravenous (IV) ABB... NaN \n",
"27 Cilta-cel:Participants who had received cilta-... NaN \n",
"28 Drug: Elranatamab \\n\\r\\nBCMA-CD3 bispecific an... NaN \n",
"29 BNCT is performed in combination with a cyclot... Interventional \n",
"30 In accordance with the ide-cel prescribing inf... NaN \n",
"31 Daratumumab\\n\\r\\nArm A: Teclistamab-daratumuma... NaN \n",
"32 Belantamab mafodotin (anti-BCMA (B-cell matura... NaN \n",
"33 NaN \n",
"34 1. Daratumumab + lenalidomide + dexamethasone ... Interventional \n",
"35 1) Induction therapy\\n\\r\\nDRD therapy 1,2 cour... Interventional \n",
"36 Patients will receive DSP-0390 orally once dai... NaN \n",
"37 Arm A\\n\\r\\nParticipants will receive bortezomi... NaN \n",
"38 [IberDd] At the First Stage, Iberdomide (CC-22... NaN \n",
"39 Induction therapy (both arm A and arm B) D-MPB... Interventional \n",
"40 OPC-415 (up to 1X10^7cells/kg)\\n\\r\\nOn 2 days\\... NaN \n",
"41 1)Arm A: Patients randomly selected group have... Interventional \n",
"42 ACNU delivery (0.25 mg/ml, 4ml) into the spin... Interventional \n",
"43 1)\\tWT1-W10 peptide immunotherapy\\n\\r\\nIntrade... Interventional \n",
"44 Subcutaneous injection of VEGFR1 and VEGFR2 pe... Interventional \n",
"\n",
"[45 rows x 32 columns]"
]
},
"execution_count": 20,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"sorted_df"
]
},
{
"cell_type": "code",
"execution_count": null,
"metadata": {},
"outputs": [],
"source": []
}
],
"metadata": {
"kernelspec": {
"display_name": "gradio",
"language": "python",
"name": "python3"
},
"language_info": {
"codemirror_mode": {
"name": "ipython",
"version": 3
},
"file_extension": ".py",
"mimetype": "text/x-python",
"name": "python",
"nbconvert_exporter": "python",
"pygments_lexer": "ipython3",
"version": "3.12.3"
}
},
"nbformat": 4,
"nbformat_minor": 2
}
|